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1. INTRODUCTION
1.1 CANCER
Synonyms- carcinoma, malignant tumour, malignant neoplasm, C, big C,
canker, carcinoma, corruption, disease, long illness, malignancy, sickness, tumor
(http://thesaurus.com/browse/cancer)
Origin of the Word "Cancer"- The word cancer came from the father of
medicine, Hippocrates, a Greek physician. Hippocrates used the Greek words,
carcinos and carcinoma to describe tumors, thus calling cancer "karkinos." The
Greek terms actually were words to describe a crab, which Hippocrates thought a
tumor resembled. Although Hippocrates may have named "Cancer," he was
certainly not the first to discover the disease. The history of cancer actually begins
much earlier.
The First Documented Case of Cancer- The world's oldest documented
case of cancer hails from ancient Egypt, in 1500 b.c. The details were recorded on a
papyrus, documenting 8 cases of tumors occurring on the breast. It was treated by
cauterization, a method to destroy tissue with a hot instrument called "the fire drill."
It was also recorded that there was no treatment for the disease, only palliative
treatment. There is evidence that the ancient Egyptians were able to tell the
difference between malignant and benign tumors. According to inscriptions, surface
tumors were surgically removed in a similar manner as they are removed today.
(http://cancer.about.com/od/historyofcancer/a/cancerhistory.htm)
Definition of cancer- Cancer is a term used for diseases in which abnormal
cells divide without control and are able to invade other tissues. Cancer cells can
spread to other parts of the body through the blood and lymph systems.
Cancer is not just one disease but many diseases. There are more than 100
different types of cancer. Most cancers are named for the organ or type of cell in
which they start - for example, cancer that begins in the colon is called colon cancer;
cancer that begins in basal cells of the skin is called basal cell carcinoma.
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Thus cancer is defined as the uncontrolled growth of abnormal cells in the
body of a living organism these cells are also called as malignant cells. These cells
form a mass called as tumours.
1). CLASSIFICATION:
The tumours can be of two types
a. Benign tumours
b. Malignant tumours
Benign tumours are generally noncancerous cells where as malignant
tumours are cancerous and can invade nearby tissues which can break away and
spread to other parts of the body.
Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a
suffix, with the Latin or Greek word for the organ or tissue of origin as the root.
For example, cancers of the liver parenchyma arising from malignant
epithelial cells is called hepatocarcinoma, while a malignancy arising from
primitive liver precursor cells is called a hepatoblastoma, and a cancer arising from
fat cells is called as liposarcoma.
For some common cancers, the English organ name is used. For example, the
most common type of breast cancer is called ductal carcinoma of the breast. Here,
the ductal refers to the appearance of the cancer under the microscope, which
suggests that it has originated in the milk ducts.
Benign tumours (which are not cancers) are named using -oma as a suffix
with the organ name as the root. For example, a benign tumour of smooth muscle
cells is called a leiomyoma (the common name of this frequently occurring benign
tumour in the uterus is fibroid). Confusingly, some types of cancer also use the -oma
suffix, examples including melanoma and seminoma.
Some types of cancer are named for the size and shape of the cells under a
microscope, such as giant cell carcinoma, spindle cell carcinoma, and small cell
carcinoma.
(Kinzler et al., 2002)
Chapter 1 Introduction
Dept. of Pharmacology 3 JKK Nattraja College of Pharmacy
2). TYPES OF CANCER:
Cancer types can be grouped into broader categories. The main categories of
cancer include:
Carcinoma - cancer that begins in the skin or in tissues that line or cover internal
organs.
Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other
connective or supportive tissue.
Leukemia - cancer that starts in blood-forming tissue such as the bone marrow and
causes large numbers of abnormal blood cells to be produced and enter the blood.
Lymphoma and myeloma - cancers that begin in the cells of the immune system.
Central nervous system cancers - cancers that begin in the tissues of the brain and
spinal cord.
3). ORIGINS OF CANCER:
All cancers begin in cells, the body's basic unit of life. To understand cancer,
it's helpful to know what happens when normal cells become cancer cells.The body
is made up of many types of cells. These cells grow and divide in a controlled way
to produce more cells as they are needed to keep the body healthy. When cells
become old or damaged, they die and are replaced with new cells.However,
sometimes this orderly process goes wrong. The genetic material (DNA) of a cell
can become damaged or changed, producing mutations that affect normal cell
growth and division. When this happens, cells do not die when they should and new
cells form when the body does not need them. The extra cells may form a mass of
tissue called a tumor.
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Not all tumors are cancerous; tumors can be benign or malignant.
 Benign tumors aren't cancerous. They can often be removed, and, in most cases,
they do not come back. Cells in benign tumors do not spread to other parts of the
body.
 Malignant tumors are cancerous. Cells in these tumors can invade nearby tissues
and spread to other parts of the body. The spread of cancer from one part of the
body to another is called metastasis.Some cancers do not form tumors. For
example, leukemia is a cancer of the bone marrow and blood.
(http://cancer.about.com/od/historyofcancer/a/cancerhistory.htm)
2). CAUSES OF CANCERS
There are different kinds of cancers which can develop in almost any organ
or tissue. The main causes of cancer are
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a. Benzene and other chemicals
b. Drinking excess alcohol
c. Environmental toxins
d. Excessive exposure to sunlight
e. Genetic problems
f. Obesity
g. Radiation
h. Viruses
However many causes which may lead to cancer are unknown. The spread of
cancer from one part to other part is called metastatis.
Free radicals compounds also cause damage to cells. These contain an
unpaired electron in the outer nucleus of the cell. The free radicals generated from
the oxygen are called ROS which can oxidise or reduce molecules.
The free radicals formed mainly by two sources in body i.e. endogenous
sources (nutrient metabolism, aging process etc) and exogenous sources (smoke,
radiation, air pollution, pesticides, chemicals etc)
3). SYMPTOMS
The symptoms of cancer are divided in to three groups:
a. Local symptoms- these are restricted only to the site of the cancer. This
includes lumps, swelling, haemorrhage, ulceration and pain.
b. Metastatic symptoms- these are symptoms due to the spread of the cancer
to other parts of the body. They include enlarged lymph nodes,
hepatomegaly, splenomegaly, which can be felt in the abdomen, pain or
fracture in the bones and neurological symptoms
c. Systematic symptoms - these occur due to distant effects of the cancer
that are not related to direct metastatic spread which may include weight
loss, fatigue, excessive sweating, anaemia and other symptoms which
may be mediated by immunological or hormonal signals from the cancer
cells.
Chapter 1 Introduction
Dept. of Pharmacology 6 JKK Nattraja College of Pharmacy
All these symptoms are not diagnostic which occur commonly in patients not having
cancer.Cancer is primarily an environmental disease with 90-95% of cases due to
environmental factors and 5-10% due to genetics. (Moscow et al., 2007)
4). PATHOPHYSIOLOGY OF CANCER
Figure – 1
In body there are cancer suppressor genes which get inactivated by mutation and
these cells gets proliferated which further more inactivates the DNA repair genes
which inactivates much more tumour suppressing genes which leads finally to
cancer. (Kim et al., 2006)
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Cancer is caused by a series of mutations. Each mutation alters the behaviour
of the cell. Cancer is fundamentally a disease where in there is a failure of tissue
regulation in the body. In order to transform in to a cancer cell the genes which
regulate the cell growth and differentiation must be altered.
The affected genes are divided in to two categories
a. Oncogenes
b. Tumour suppressor genes
Oncogenes are those genes which are responsible for the cell growth and
reproduction. (Croce, 2008)
Tumour suppressor genes are vice-versa (i.e. Inhibit the cell division and
survival). Malignant transformation can occur through formation of novel oncogens
due to over expression or by under expression of tumour suppressing genes.
Genetic changes occur in different levels by different mechanisms. The gain
or loss of a chromosome is due to error in mitosis or by mutations which change the
nucleotide sequence of DNA.
According to the National Cancer Institute in 2010, the most common
cancers (excluding non-melanoma skin cancers) are listed below.
Cancer type Estimated new cases Estimated deaths
Bladder 70,530 14,680
Breast (female-male) 207,090-1,970 39,840-390
Colon and rectal (combined) 142,570 51,370
Endometrial 43,470 7,950
Kidney (renal cell) 53,581 11,997
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Leukemia 43,050 21,840
Lung (including bronchus) 222,520 157,300
Melanoma 68,130 8,700
Non-Hodgkin lymphoma 65,540 20,210
Pancreatic 43,140 36,800
Prostate 217,730 32,050
Thyroid 44,670 1,690
Some other cancers include brain cancer, hodgkin’s lymphoma, testicular
cancer, liver cancer, uterine cancer.
The three most common cancers in men, women and children are as follows:
 Men: Prostate, lung, and colorectal.
 Women: Breast, colorectal, and lung.
 Children: Leukemia, brain tumours, and lymphoma. (Jermal et al., 2011)
5). SCREENING AND TESTING TO DETECT CANCER:
 Imaging Tests
 Laboratory Tests
 Other Testing Information
5.1) IMAGING TESTS:
A) Mammograms:
A fact sheet that defines screening and diagnostic mammograms. Discusses
mammography screening guidelines and risk factors for breast cancer.
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B) Find an FDA Certified Mammography Facility:
Find an FDA certified mammography facility near where you live or work.
C) Computed Tomography (CT):
A fact sheet that describes the CT scan procedure and technology and its uses
in diagnosis and treatment.
5.2) LABORATORY TESTS:
A) Interpreting Laboratory Test Results:
A fact sheet that describes the role of screening and diagnostic laboratory
tests. Includes a brief discussion of factors affecting the results.
B) Pap Test:
A fact sheet that describes the Pap test procedure, possible results, and the
link between HPV and cervical cancer.
C) Pap Tests:
Provides information about the importance of routine Pap testing in
preventing and detecting cervical cancer, when to get a Pap test, and what to expect
during screening. For rarely- or never-screened women.
D) Prostate-Specific Antigen (PSA) Test:
A fact sheet that describes the PSA screening test for prostate cancer and
explains the benefits and limitations of the test.
E) Tumor Markers:
A fact sheet that defines tumor markers and describes how they can be used
to aid diagnosis and treatment.
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5.3) OTHER TESTING INFORMATION:
A) Understanding Cancer Series: Gene Testing
This tutorial illustrates what genes are, explains how mutations occur and
are identified within genes, and discusses the benefits of gene testing for cancer and
other disorders.
B) Proteomics and Cancer:
This fact sheet describes proteomics (the study of proteins and how they
respond to the needs of the body or in disease). This research may lead to new ways
to diagnose cancer and identify the best treatments for individual patients.
C) What You Need To Know About™ Cancer Index:
Learn the symptoms of cancer - and symptoms of many cancer types - by viewing
the online booklets listed here
.(http://www.cancer.gov/cancertopics/screening/types)
6). TREATMENT TYPES:
a) SURGERY:
Surgery can be used to diagnose, treat, or even help prevent cancer in some
cases. Most people with cancer will have some type of surgery. It often offers the
greatest chance for cure, especially if the cancer has not spread to other parts of the
body.
b) CHEMOTHERAPY:
Chemotherapy (chemo) is the use of medicines or drugs to treat cancer. The
thought of having chemotherapy frightens many people. But knowing what
chemotherapy is, how it works, and what to expect can often help calm your fears. It
can also give you a better sense of control over your cancer treatment.
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c) RADIATION THERAPY:
Radiation therapy uses high-energy particles or waves to destroy or damage
cancer cells. It is one of the most common treatments for cancer, either by itself or
along with other forms of treatment.
d) TARGETED THERAPY
Targeted therapy is a newer type of cancer treatment that uses drugs or other
substances to more precisely identify and attack cancer cells, usually while doing
little damage to normal cells. Targeted therapy is a growing part of many cancer
treatment regimens.
e) IMMUNOTHERAPY:
Immunotherapy is treatment that uses your body's own immune system to
help fight cancer. Get information about the different types of immunotherapy and
the types of cancer they are used to treat.
f) HYPERTHERMIA:
The idea of using heat to treat cancer has been around for some time, but
early attempts had mixed results. Today, newer tools allow more precise delivery
of heat, and hyperthermia is being studied for use against many types of cancer.
g) BONE MARROW AND PERIPHERAL BLOOD STEM CELL
TRANSPLANT:
Here we offer a review of bone marrow transplants and other types of stem
cell transplants that are used to treat cancer.
h) PHOTODYNAMIC THERAPY:
Photodynamic therapy or PDT is a treatment that uses special drugs, called
photosensitizing agents, along with light to kill cancer cells. The drugs only work
after they have been activated or "turned on" by certain kinds of light.
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i) LASERS IN CANCER TREATMENT:
Lasers, which are very powerful, precise beams of light, can be used instead
of blades (scalpels) for very careful surgical work, including treating some cancers.
j) BLOOD PRODUCT DONATION AND TRANSFUSION:
Transfusions of blood and blood products temporarily replace parts of the
blood when a person's body can't make its own or has lost them from bleeding.
k) HORMONE REPLACEMENT THERAPY VS. HORMONAL
TREATMENT:
In this therapy, doctors attempt to block the production of hormones that are
feeding the growth of the cancer.
l) MOLECULAR TARGETED THERAPY:
Molecular targeted therapies may become a revolutionary change in the
treatment of cancer.
(http://www.cancer.org/Treatment/TreatmentsandSideEffects/Treatmen
Types/index)
7). PREVENTION
The risk of cancer can be reduced by following methods
a. Healthy diet
b. Regular exercise
c. Limiting alcohol
d. Maintain healthy weight
e. Less exposure to radiation and toxic chemicals
f. Reducing sun exposure
g. Not smoking or chewing tobacco
(Thum et al., 2007)
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8). ALTERNATIVE TREATMENTS
Alternative cancer treatments include alternative medicine of non-related
interventions that do not fit the regular western medicine and include mind–body
interventions, herbal preparations, massage, acupuncture, reiki, electrical stimulation
devices, and a variety of strict dietary regimens.
Alternative cancer treatments have never been shown to be effective at
killing cancer cells in research studies, but remain popular in some cultures and
religions.
9). PALLIATIVE CARE
Palliative care is a multidisciplinary approach to symptom management that
aims to reduce the physical, emotional, spiritual, and psycho-social distress
experienced by people with cancer. Unlike treatment that is aimed at directly killing
cancer cells, the primary goal of palliative care is to make the person feel better as
soon as possible. (Astin et al., 1998)
10). HOME REMEDIES FOR CANCER AND TUMOURS
Turmeric - contains a therapeutic compound called curcumin, turmeric has been
shown to fight cancer and tumourous growths.
Green Tea Extract - Green tea extract contains a chemical called ECGC, which
neutralizes highly reactive free radicals that cause cell damage. Green tea extract
also inhibits cell replication, a main feature of cancer.
Maitake Extract - from the Chinese mushroom, maitake extract aids in the
destruction of cancer cells and combats the spread of tumours.
Red Clover - The flowers from this three-leafed herb contain four anti-tumor
compounds. Also, the red clover contains large amounts of tocopherol, a powerful
antioxidant that combats cell-destroying free radicals.
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Other Important Nutrients for Cancer Prevention and Treatment
Quercetin - known as citrus bioflavanoid, quercetin may reverse abnormal cell
growth and inhibit prostate cancer.
Beta Glucan - These are polysaccharides they can boost your immune system.
Vitamin K and Vitamin C - taken together these vitamins might inhibit cancerous
growths. Vitamin K has shown promise in treating liver cancer.
(Herbs for Cancer - Cancer herbs, mht, Herbal - Supplements-Guide.Com.)
1.2. INDIAN MEDICINAL PLANTS HAVING ANTICANCER ACTIVITY
Cancer is the leading cause of death in developing countries like India. As
there is an enormous increase in the population day by day, the alternative therapy in
the market is getting its glimpse. The cheap herbal drug treatment may highly be
recommended to the rural and poor people to treat effectively the cancers of various
type is an ideal choice. Based on that the siddha medicines are coming up in
combination with metals and other essential supplements to improve the immune
status of the cancer patients in India.
S.no Name of the plant Family Parts
used
1. Calotrophis gigantea Asclepiadaceae Whole plant
2. Cajanus cajan Fabaceae Leaves
3. Butea monosperma Fabaceae Bark
4. Bauhinia variegate Caesalpinaceae Root
5. Bacopa monnieri Scropulariaceae Whole plant
6. Azadirachta indica Meliaceae Bark
7. Asparagus racemosus Liliaceae Root
8. Aphanamixis polystachya Meliaceae Bark
9. Aloe barbadensis Liliaceae Leaf juice
10. Alium cepa Liliaceae Bulb
11. Acorus calamus Araceae Rhizome
12. Cassia absus Caesalpinaceae Leaves
13. Cassia auriculata Caesalpinaceae Root
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14. Cassia senna Caesalpinaceae Leaves
15. Catunaregum spinosa Rubiaceae Bark/Fruit
16. Citrullus colocynthis Cucurbitaceae Root
17. Citrus medica Rutaceae Root
18. Cissus quadrangularis Vitaceae Whole plant
19 Clerodendrum serratum Verbanaceae Root
20 Clerodendrum viscosum Verbanaceae Leaves
21 Crinum asiaticum Amaryllidaceae Bulb
22. Daucus carota Apiaceae Root
23. Embelia ribes Myrsinaceae Fruit
24 Flacourtia jangomos Flacourtiaceae Bark/Leaf
25 Jatropha curcas Euphorbiaceae Leaves, seed, oils
26 Kaempferia galanga Zingiberaceae Rhizome
27 Kaempferia rotunda Zingiberaceae Tubers
28 Lanata camara Verbanaceae Whole plant
29 Lens culinaris medikus Fabaceae Seed
30 Limonia acidissima Rutaceae Fruit
31 Macrotyloma uniflorum Fabaceae Seed
32 Mimosa pudica Mimosaceae Whole plant
33 Nicotiana tabacum Solanaceae Leaves
34 Operculina turpethum Convolvulaceae Root
35 Rhinacanthus nasuta Acanthaceae Whole plant
36 Salvadora persica Salvadoraceae Bark, Leaf, Shoot, Fruit
39 Symplocus cochinchinensis Symplocaceae Bark
40 Tylopora indica Asclepiadaceae Root, Leaf
41 Vernonia cinerea Asteraceae Whole plant
42 Vitex trifolia Verbanaceae Leaf
43 Zanthoxylum armatum Rutaceae Bark,Fruit
44. Xanthium strumarium Compositae Root
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Hence many Indian medicinal plants have anticancer activities. Different
parts of the plants used for anticancer activities.
(Nair et al., 2010), (Paolo Scartezzini and Ester Speroni, 2000), (Dhanamani et
al., 2011), (Sakarkar and Deshmukh, 2011)
1.4. WHAT ARE FLAVONOIDS AND THEIR ROLE AS ANTICANCER
AGENTS?
Flavonoids (or bioflavonoids) (from the Latin word flavus meaning yellow),
also collectively known as Vitamin P and citrin, are a class of plant secondary
metabolites or yellow pigments having a structure similar to that of flavones.
According to the IUPAC nomenclature they can be classified into:
 flavonoids, derived from 2-phenylchromen-4-one (2-phenyl-1, 4-benzopyrone)
structure (examples: quercetin, rutin).
 isoflavonoids, derived from 3-phenylchromen-4-one (3-phenyl-1,4-
benzopyrone) structure
 neoflavonoids, derived from 4-phenylcoumarine (4-phenyl-1,2-benzopyrone)
structure. (Flavanoids IUPAC compendium of chemical technology)
The three flavanoids classes above are all ketone-containing compounds, and
as such, are flavanoids and flavonol.
Flavonoids are the most important plant pigments for flower coloration
producing yellow or red/blue pigmentation in petals designed to attract pollinator
animals.
Flavonoids secreted by the root of their host plant help Rhizobia in the
infection stage of their symbiotic relationship with legumes like peas, beans, clover,
and soy.
In addition, some flavanoids have inhibitory activity against organisms that
cause plant disease e.g. Fusarium oxysporum.
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1). SOURCES
Good sources of flavanoids include all citrus fruits, berries, ginkgo biloba,
onions (particularly red onion), parsley, pulses, tea (especially white and green tea),
red wine, sea buckthorn, and dark chocolate (with a cocoa content of seventy
percent or greater).
Over 5000 naturally occurring flavanoids have been characterized from
various plants.
Flavonoids (specifically flavanoids such as the catechins) are "the most
common group of polyphenolic compounds in the human diet and are found
ubiquitously in plants". Flavonols, the original bioflavonoids such as quercetin, are
also found ubiquitously, but in lesser quantities. (Brown, 1980), (Justesen et al.,
2001)
2). EFFECTS ON HUMAN HEALTH
Flavonoids might induce mechanisms that affect cancer cells and inhibit
tumor invasion. In preliminary studies, UCLA cancer researchers proposed that
smokers who ate foods containing certain flavanoids, such as catechins found in
strawberries and green and black teas, kaempferol from brussel sprouts and apples,
and quercetin from beans, onions and apples, may have reduced risk of obtaining
lung cancer.
The widespread distribution of flavonoids, their variety and their relatively
low toxicity compared to other active plant compounds (for instance alkaloids) mean
that many animals, including humans, ingest significant quantities in their diet.
Preliminary research indicates that flavonoids may modify allergens, viruses, and
carcinogens, and so may be biological "response modifiers". In vitro studies show
that flavonoids also have anti-allergic, anti-inflammatory, anti-microbial, anti-
cancer, and anti-diarrheal activities.
3). ANTIOXIDANT ACTIVITY IN-VITRO
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Flavonoids (both flavonols and flavanols) are most commonly known for
their antioxidant activity. Additionally, at high experimental concentrations that
would not exist in vivo, the antioxidant abilities of flavanoids in vitro are stronger
than those of vitamin C & E.
4). WHAT DO THEY DO?
As antioxidants, some flavanoids such as Quercetin protect LDL cholesterol
from oxidative damage.
The ability to limit inflammation gives the flavanoids their disease fighting
potential. They actively prevent the release of histamine in the body - this is the
agent responsible for most allergy symptoms like congestion.
Flavonoids also actively scavenge free radicals they tend to boost immune
system functioning and strengthen the blood vessels, thereby increasing the blood
flow.
Flavonoids exhibit potent anticancer effects, although the exact target of
such inhibition has not been definitely established, given the recent evidence for a
prominent role for reactive oxygen species (ROS) in carcinogenesis. It is tempting to
speculate that flavanoids inhibit carcinogenesis due to ROS scavenging. However
there have been a number of reports that directly contradict the potential role of
flavanoids as antioxidants/anticancer agents.
Flavonoid and related compound are effective in scavenging DPPH radical,
hydroxyl radical and in metal-chelating capacity. (Irfan khan 2011)
a). QUERCETIN
Quercetin, a flavanoids and more specifically a flavonol, is the aglycone
form of other flavanoids glycosides, such as rutin and quercitrin, found in citrus
fruit, buckwheat and onions. Quercetin forms the glycosides, quercitrin and rutin,
together with rhamnose and rutinose, respectively.
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Although there is preliminary evidence that asthma, lung cancer and breast
cancer are lower among people consuming higher dietary levels of quercetin, the
U.S. Food and Drug Administration (FDA), EFSA and the American Cancer Society
have concluded that no physiological role exists. The American Cancer Society
states that dietary quercetin "is unlikely to cause any major problems or benefits."
(Pawlknekt et al., 2002)
b). EPICATECHIN (EC)
Epicatechin may improve blood flow and has potential for cardiac health.
Cocoa, the major ingredient of dark chocolate, contains relatively high amounts of
epicatechin and has been found to have nearly twice the antioxidant content of red
wine and up to three times that of green tea in vitro. (Lee et al., 2003)
1.5. PHYTOSTEROLS
Phytosterols (also called plant sterols) area group
of steroidalcohols, phytochemicals naturally occurring in plants. Plants contain a
range of phytosterols. They act as a structural component in the cell membrane, a
role that, in mammalian cells, is played by cholesterol.
1). SOURCES
Phytosterols occur naturally in small quantities in vegetable oils,
especially sea buckthorn oil (1640 mg/100g oil), corn
oil (968 mg/100g), and soybean oil (327 mg/100g oil). One such phytosterol
complex, isolated from vegetable oil, is cholestatin, composed of campesterol,
stigmasterol, and brassicasterol, and is marketed as a dietary supplement. They are
white powders with mild, characteristic odor, insoluble in water and soluble
in alcohols. They have applications in medicine and cosmetics and as a food
additive taken to lower cholesterol. (Pennigton, 2005)
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2). USES
As a food ingredient or additive, phytosterols have cholesterol-lowering
properties (reducing cholesterol absorption in intestines).
The FDA has approved the following claim for phytosterols "Foods
containing at least 0.4 gram per serving of plant sterols, eaten twice a day with
meals for a daily total intake of at least 0.8 gram, as part of a diet low in saturated fat
and cholesterol, may reduce the risk of heart disease." (Ostlund et al., 2003)
Researchers in Uruguay who conducted a small case study suggested an
association between dietary sterol intake and decreased risk for the development of
gastrointestinal cancers, However, a subsequent large-scale study from the
Netherlands reported that high dietary intake of plant sterols was not associated with
a lower risk of colon and rectal cancers. (Lunasin-Cholesterol Reducing Soy
Peptide That’s Natural and Beneficial.htm., Copyright 2011)
Phytosterols demonstrated cholesterol lowering effects and reduction in
coronary heart disease risks. Several studies have indicated that phytosterols may
possess anticancer activity. Cytotoxicity of plant sterols particularly by stigmasterol
against cancer cells were evidenced towards breast cancer cells (Awad et al.,
2000a). Moreover, cytotoxicity of plant sterols was also observed in colon cancers
cells. (Chong et al., 2010)
3). HOW DO THEY ACT ON CANCER
Phytosterols (PS) or plant sterols are structurally similar to cholesterol. The
most common PS are beta-sitosterol, campesterol and stigmasterol. Epidemiologic
and experimental studies suggest that dietary PS may offer protection from the most
common cancers in western societies, such as colon, breast and prostate cancer. This
review summarizes the findings of these studies and the possible mechanisms by
which PS offer this protection. These include the effect of PS on membrane structure
and function of tumor and host tissue, signal transduction pathways that regulate
tumor growth and apoptosis, immune function of the host and cholesterol
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metabolism by the host.(Awad et al., 2000), (Lunasin-Cholesterol Reducing Soy
Peptide That’s Natural and Beneficial. htm., Copyright 2011)
1.5.1. BETA-SITOSTEROL
β-Sitosterol is one of several phytosterols (plant sterols) with chemical
structure similar to that of cholesterol. Sitosterols are white, waxy powders with a
characteristic odor. They are hydrophobic and soluble in alcohols.
1). SOURCES
It is widely distributed in the plant kingdom and found in Nigella sativa,
pecans, Serenoa repens (saw palmetto), avocados, Cucurbita pepo(pumpkin
seed),Pygeum africanum, cashew fruit, rice bran, wheatgerm, cornoils, soybeans, sea
buckthorn, wolfberries, and Wrightia tinctoria.
2). USES
Alone and in combination with similar phytosterols, β-sitosterol
reduces blood levels of cholesterol, and is sometimes used in
treating hypercholesterolemia. β-Sitosterol inhibits cholesterol absorption in the
intestine. When the sterol is absorbed in the intestine, it is transported by
lipoproteins and incorporated into the cellular membrane. Phytosterols and
phytostanols both inhibit the uptake of dietary and biliary cholesterol, decreasing the
levels of LDL and serum total cholesterol. Because the structure of β-sitosterol is
very similar to that of cholesterol, β-sitosterol takes the place of dietary and biliary
cholesterol in micelles produced in the intestinal lumen. This causes less cholesterol
absorption in the body.
One small study shows a positive effect on male hair loss in combination
with Saw palmetto.
In Europe, β-sitosterol is used in herbal therapy, especially in the treatment
of benign prostatic hyperplasia (BPH).
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It is also used in Europe for the treatment of prostatic carcinoma and breast
cancer, although the benefits are still being evaluated in the US. ( Berges et al.,
1995)
1.6. SYNTHETIC DRUGS USED IN THE TREATMENT OF TUMOURS
Chemotherapy is the treatment of an ailment by chemicals especially by
killing micro-organisms and other malfunctions of the body.
The majority of chemotherapeutic drugs can be divided in to alkylating
agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors,
and other antitumour agents. All of these drugs affect cell division or DNA synthesis
and function in some way.
Some newer agents do not directly interfere with DNA. These include
monoclonal antibodies and the new tyrosine kinase inhibitors e.g. imatinib mesylate
(Gleevec or Glivec), which directly targets a molecular abnormality in certain types
of cancer (chronic myelogenous leukemia, gastrointestinal stromal tumours). These
are examples of targeted therapies.
In addition, some drugs that modulate tumor cell behaviour without directly
attacking those cells may be used. Hormone treatments fall into this category.
The different types of anti cancer agents used in chemotherapy are as follows
TYPES EXAMPLES
Alkylating agents Cisplatin, carboplatin and oxaliplatin
Anti-metabolites Purines - azathioprine, mercaptopurine
Pyramidines - 5-fluro uracil
Plant alkaloids Vincristine, vinblastine, vindesine,
vinorelbine
Podophyllotoxin Etopside, teniposide
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Taxanes Docetaxel
Topisomerase inhibitors Type 1 – irinotecan, topotecan
Type 2- amasacrine, etopside
Cytotoxic antibiotics Actinomycin, anthracyclines, belomycin
Others Hydroxyurea, procarbazine,
carboplatin,cisplatin
Drugs atering hormonal milieu Prednisolone, tamoxifen, hydroxyl
progesterone, fosfestrol, letrozole etc
1.7. STANDARD DRUG USED FOR THE PRESENT STUDIES
Fluorouracil (5-FU or f5U) is a drug that is a pyrimidine analog which is
used in the treatment of cancer. It is a suicide inhibitor and works through
irreversible inhibition of thymidylate synthase. It belongs to the family of drugs
called antimetabolites.
1). MECHANISM OF ACTION
As a pyrimidine analogue, it is transformed inside the cell into different
cytotoxic metabolites which are then incorporated into DNA and RNA, finally
inducing cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize
DNA.
It is an S-phase specific drug and only active during certain cell cycles. In addition
to being incorporated in DNA and RNA, the drug has been shown to inhibit the
activity of the exosome complex, an exoribonuclease complex of which the activity
is essential for cell survival. (Thripathi, 2008)
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2). USES
The chemotherapy agent 5-FU (fluorouracil), which has been in use against
cancer for about 40 years, acts in several ways, but principally as a thymidylate
synthase inhibitor, interrupting the action of this enzyme blocks synthesis of the
pyrimidine thymidine, which is a nucleotide required for DNA replication.
Thymidylate synthase methylates deoxyuridine monophosphate (dUMP)
into thymidine monophosphate (dTMP). Administration of 5-FU causes a scarcity in
dTMP, so rapidly dividing cancerous cells undergo cell death via thymineless death.
Like many anti-cancer drugs, 5-FU's effects are felt system wide but fall
most heavily upon rapidly dividing cells that make heavy use of their nucleotide
synthesis machinery, such as cancer cells (other parts of the body with rapidly
dividing cells include the cells lining the digestive tract).
Some of its principal uses are in colorectal cancer, and pancreatic cancer, in
which it has been the established form of chemotherapy for decades (platinum-
containing drugs approved for human use in the US since 1978 are also very well
established). It is also sometimes used in the treatment of inflammatory breast
cancer, an especially aggressive form of breast cancer.
5-FU is also used in ophthalmic surgery, specifically to augment
trabeculectomy (an operation performed to lower the intraocular pressure in patients
with glaucoma) in patients deemed to be at high risk for failure. 5-FU acts as an
anti-scarring agent in this regard, since excessive scarring at the trabeculectomy site
is the main cause for failure of the surgery.
Fluorouracil can be used topically (as a cream) for treating actinic (solar)
keratoses and some types of basal cell carcinomas of the skin. It is often referred to
by its trade names Efudex, Carac or Fluoroplex.
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Due to Fluorouracil's toxicity and the fact that it can be manufactured using
the same reaction as uracil, its precursor, 5-Fluoroorotic Acid, is commonly used in
laboratories to screen against organisms capable of synthesizing uracil. (Longley et
al., 2003)
1.8. DIFFERENT METHODS FOR SCREENING OF NEW ANTICANCER
MOLECULES
The main aims of screening methods are
a. To test the ability of a compound to kill cancerous cells.
b. To discriminate between replicating and non-replicating cells.
c. To find the potency of the drug
d. Effectiveness of drug and specific site of action
The different methods of screening are
1. In-vitro methods
2. In-vivo methods
3. Cell line methods
1). IN-VITRO METHODS
In-vitro testing is preferred to in-vivo testing for testing the potential of
chemotherapeutic agents. In-vitro cultures can be cultivated under a controlled
environment (pH, temperature, humidity, oxygen/carbon dioxide balance etc)
resulting in homogenous batches of cells and reducing the mistakes.
Different types of in-vitro methods include
1. Tetrazolium salt assay(MTT)
2. Sulphorhodamine B assay
3. 3H thymidine uptake
4. Dye exclusion tests
5. Clonogenic assay
Chapter 1 Introduction
Dept. of Pharmacology 26 JKK Nattraja College of Pharmacy
6. Cell counting assay
These methods used to find different type of properties in culture cells and
thus used to detect the therapeutic effect of the drug and potency. These tests are
frequently used for screening of anti-cancer drugs:
S.NO ASSAY PROPERTIES
1 Tetrazolium salt assay(MTT) Enzymatic properties
2. Sulphorhodamine B assay Protein content and synthesis
3. 3H thymidine uptake DNA content and synthesis
4. Dye exclusion assay Membrane integrity of cell
5. Clonogenic assay Clonogenic properties
6. Cell counting assay Cell divison
2). IN-VIVO METHODS
The in-vivo testing is performed on animals to test the efficacy of the drug
on animals and to check the different parameters and compare them with the
standard.
1. DMBA induced mouse skin papillomas, rat mammary gland carcinogenesis,
oral cancer in hamster.
2. N-methyl, N- nitrosurea(NMU) induced rat mammary gland carcinogenesis.
3. NMU induced tracheal squamous cell carcinoma in hamster.
4. N, N diethyl nitrosamine (DEN) induced lung asenocarcinoma in hamster.
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5. 1, 2 Dimethyl hydralazine (DMH) inducer colorectal adenocarcinoma in rat
and mouse.
6. Azoxymethane (AOM) induced aberrant crypt foci in rats.
7. 1- Butyl-n-(4 hydroxy butyl)- nitrosamine induced bladder carcinoma in
mouse.
8. 2- Methylcholanthrene induced fibrosarcoma tumor in mouse.
9. 3-Methylcholanthrene induced skin tumours in mouse.
10. Benzopyrene induced fore stomach tumours in mouse.
In all these in-vivo methods the cancer is induced by some chemicals and
then the drug given by different routes and the efficacy measured and compared
with that of the standard drugs and thus the activity of the drug found out
statistically.
3). CELL LINE METHODS
In this method of studies the cancer cells are directly induced into the animal
and propagated to induce cancer in the animals. The specified number of cells
inoculated in to a sensitive mouse strains and tumor developed rapidly as compared
to chemical carcinogen. It is much faster and less time consuming model than other
methods.
Different types of cell line techniques are
1. Hollow fiber technique.
2. Use of kenografts.
3. Nude mouse models.
4. New born rat model.
5. Transgenic mouse model.
6. DAL induced mouse model. (Gupta, 2008)
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a). DAL (DALTON’S ASCITES LYMPHOMA) MOUSE MODEL
Ascites is excess fluid in the space between the tissues lining the abdomen
and abdominal organs (the peritoneal cavity). (Ascites medline plus, A service of
US national library of Medicine NIH national institute of health)
Lymphomas are cancers that begin in the cells of the immune system
 It is a tumor cell line originally grown from a tumour of the thymus.
 It is propagated by growing as ascites tumour in mice.
 We can induce both ascites tumour and solid tumours using DAL
cells.
 It is easy to maintain in vivo.
 It is not an immunogenic.
The solid tumours were obtained by injecting the DAL cell lines
subcutaneously in to the mouse hind paw which gets increased in the mass and
becomes solid. This cannot be propagated like the ascites lymphoma.
b). MAINTENANCE OF CELL LINES:
Dalton’s lymphoma ascites tumour cell lines (DLA), originally obtained
from Amala Cancer Institute, Thrissur, Kerala and was propagated as transplantable
tumours in the peritoneal cavity of the mice were used for the study.
The tumour cell lines were maintained by serial peritoneal cavity I.P
transplantation in mice.
The fully grown tumour cell lines were aspirated from mouse peritoneal
cavity and mixed with PBS solution and mixed with tryphan blue solution. Taken
that suspended solution and counted the number of cells present in one ml by using
tryphan blue exclusion method and adjust the cell count to 1×106. Then PBS
solution was used and the cells were mixed well and were injected intraperitonially
in to a new healthy mouse and thus the cancer got developed with in 10-15days of
time.
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2. LITERATURE REVIEW
2.1. TAXANOMY OF THE PLANT
Domain : Eukaryota- Whittaker &Margulis, 1978 - eukaryotes
Kingdom : Plantae- Haeckel, 1866 - Plants
Subkingdom : Viridaeplantae- Cavalier-Smith, 1981
Phylum : Tracheophyta- Sinnott, 1935 Ex Cavalier-Smith, 1998
–
Vascular Plants
Subphylum : Euphyllophytina
Infraphylum : Radiatopses- Kenrick& Crane, 1997
Class : Magnoliopsida- Brongniart, 1843 - Dicotyledons
Subclass : Magnoliidae- NovKk Ex Takhtajan, 1967
Superorder : Magnolianae- Takhtajan, 1967
Order : Magnoliales- Bromhead, 1838
Family : Asclepiadaceae
Subfamily : Magnolioideae
Genus : Wattakaka- Linnaeus, 1753
Specific epithet          : volubilis - Stapf
Botanical name : Wattakaka volubilis Stapf
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2.2. SYNONYMS
1. Asclepias volubilis L. F.
2. Dregea Volubilis
3. Dregea volubilis (L. F.) Benth. Ex Hook. F.
4. Marsdenia Volubilis
5. Marsdenia volubilis (L. F.) Cooke
6. Schollia volubilis (L. F.) Jacq. Ex Steud.
( Frederick G. Meyer "Magnoliaceae". in Flora of North America Vol. 3.
Oxford University Press. Online at EFloras.org )
2.3. VERNACULAR NAMES
Common name : Sneeze Wort, Cotton milk plant, Green milkweed
climber, Green wax flower, Sneezing silk
Telugu : dugdhive
Tamil : koti-p-palai
Bengal : tita kunga
Assamese : Khamal lata
Hindi : akad bel, harandodi, nak-chikni
Malayalam : velipparuthi
Marathi : harandodi, nakhasikani
Telugu : dudipalatiga
Kannada : dugdhive
Bengali : tita kunga
Oriya : dudghika
Gujarati : malati
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Sanskrit : hemajivanti
( http://www.flowersofindia.in/catalog/slides/Sneeze%20Wort.html )
2.4. GEOGRAPHICAL DISTRIBUTION
It is recorded from Nepal, India, Bangladesh, Sri Lanka, Indo-China,
southern China, Taiwan, Peninsular, Maleshia, Java and the Philippines
2.5. DESCRIPTION
This is a large twing shrub,which can reach up to 10 m. tall.The young stems
are densely hairy but later hairless.
The leaves are arranged opposite,simple and entire,broadly ovate,measuring
7-18.5 cm x 5-13 cm obtuse to truncate or subcordate at base,acuminate at
apex,thinly leathery and pinnate veined.The petiole is 2.5-4.5 cm
long,furrowed,hairless or hairy.The stipules are absent.
The inflorescence is umbrella-shaped cyme,which is situated between the
petioles of a leaf-pair and many flowered.The peduncle is 2.5-7.5 cm long.The
flowers are bisexuals,regular and 5-merous.The peducle is thin and up to 2.5 cm
long.The sepal is on the inside,with 5 basal glands, 3 mm long segments and
spreadings.The petal is bell shaped to rotate,12-16 cm in diameter, bright green ,
hairless and with obtuse segments.The stamens are inserted at the base of petals,
with connate filaments, anther with short apical membrane overarching the stigma
and with solitary pollinium in each anther cell.The corona scales are about 4 mm in
diameter which are inserted in staminal tube. There are two superior ovaries, free 1-
celled with two discoid stigma.
The consist of (1-) 2 ovoid- to lance shaped follicles which is 10-15 cm
long, blunt to slightly acute finely longitudenaly ribbed and many seeded.
The seeds are with about 4 cm long coma
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2.6. ECOLOGY / CULTIVATION
In Malaysian region,W. volubilis occurs in brushwoods and village-groves in
lowlands.However in mainland Asia, it can be found in a variety of habitats
including montane forests
(http://www.globinmed.com/index.php?option=com_content&view=article&id=62
793:dregea-volubilis-lf-benth-ex-hookf&catid=368:d)
2.7. CHEMICAL CONSTITUENTS
Drevogenin D has been isolated from seeds; hydrolysate of seed extract
yields drevogenins B, D, and P, D-cymarose, (+)methyl pachybioside, oleandrose,
pachybiose and digitoxose. A new glycoside - dregoside A along with drevogenin A
and drebbysogenin G has also been isolated from this plant.
(http://www.mpbd.info/plants/wattakaka-volubilis.php)
2.8. PARTS OF PLANTS GENERALLY USED
The leaves are much employed as an application to boils and abscesses.
The roots and tender stalks are considered emetic and expectorant. The young roots
are cut and the exuding juice is inserted into the nose to cause sneezing.
(http://www.flowersofindia.in/catalog/slides/Sneeze%20Wort.html)
2.9. THERAPEUTIC USES
Leaves used as application to boils and abscesses. Roots and tenderstalks
used as emetic and expectorant. juice exuding from cut roots are inserted into the
nose to cause sneezing. in South EastAsia used as antifebrile and emetic. used to
treat hematemesis, sore throat, carbuncles, eczema, asthma and as antidote for
poison.
(http://www.stuartxchange.org/GreenWaxFlower.html))
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2.10. GENERAL VIEW OF HERBS
Now a day the era of everything is herbal and natural. Millions of “all
natural” and “all herbal” health and dietary supplements are ruling the markets
today.
The relationship between natural herbal healing and health is well
established. Herbs are used for a wide range of health concerns. They are very useful
for supporting body detoxification, supporting organs and systems, stress relief and
building health.
For thousands of years traditional wisdom has dictated the preparation and
use of natural healing herbs. When we work with the plants in partnership and
respect, we are more likely to realize the benefits of natural herbal healing.
All herb properties can be placed in one of three general classifications:
Detoxification: When toxins accumulate in the system, they must be
removed, or disease will manifest. Herbs that help detoxify can be used in teas and
poultices. There are also herbs with specific properties that influence various parts of
the body such as herbs with laxative properties cleanse the bowel diuretic herbs will
cleanse the kidneys plants that have alterative properties will aid in detoxifying the
blood, treat skin diseases, mucous congestion, lung conditions and constipation.
System Relief: There are many herbs that can counteract problems and
relieve symptoms. Some of these actions include antibiotics, antiseptics,
antispasmodics, aromatics, carminatives, sedatives, demulcents, diaphoretics,
emollients, stimulants and styptics.
Building and Toning: Herbs to strengthen the body, improving the
functions of the internal organs and strengthening the body’s resistance to disease.
These herbs will help with recovery from acute ailments, injury, surgery anemia,
impotence, miscarriage and childbirth. They are also used for chronic diseases and
emotional instability. Building and toning herbs acts as aphrodisiacs, astringents,
cardiac tonics, digestives, diaphoretics, nerviness, nutritives, stomachic’s,
vulneraries.
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2.10.1. ADVANTAGES OF NATURAL HERBS
 Natural herbs should be considered especially when we find that synthetic
drug treatments are not helping you with our symptoms. A recent study
showed that more and more people are turning to natural herbal remedies for
treating their illnesses. This number is set to increase, as the benefits of using
all natural substances as compared to synthetic drugs become more publicly
known.
 The healing benefits from natural herbal remedies can be in only a few ways.
One may choose to consume the herbs raw or you can take capsules
containing herbs that are ground.
 Making tea out of natural herbal remedies is also very popular with many
people. Herbal teas such as chamomile, dandelion, and many others are now
widely sold.
 Another method of gaining from natural herbal remedies is to remove the
essential oils found in the herb and use them as a type of ointment or in
aromatherapy.
 Natural herbal remedies also tend to be less expensive than drug remedies.
As with any type of medication, you need to ensure that it will not counteract
any other medications that you may be taking.
 However, what is beneficial to know about natural herbal remedies is that
they are much more well-tolerated by your body than synthetic drugs, hence
fewer side effects were expected.
 Without a prescription, you can go to the health food store and buy whatever
you want. However, it is always wise to consult with your doctor first before
taking ANY medications.
 Potency may vary, depending on genetic variation of different strains of
herbs, growing conditions, timing and method of harvesting, exposure to air,
light and moisture over time and type of preservation.
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It is your responsibility to take care of your own health. Hence, it is in our
interest to be aware about all of the options that are available when it comes to
treating various ailments and illnesses. Synthetic drugs are not the only option. So
do take the time to learn about how natural herbal remedies can help in your specific
ailment.
NOTE - Still there are no guarantees when using natural herbal remedies, although
there are many who have reported good success with this form of treatment. Hence
one will find that there are many forums discussing about the efficiency of some of
the natural herbal remedies. Natural herbal remedies are not subject to the various
tests that synthetic drugs go through because major pharmaceutical companies make
more money promoting clinical drugs and would therefore channel more of their
money and resources there.
If one finds themselves prone to getting side effects when you take synthetic
drugs, natural herbal remedies may just be the solution that you need.
(Prema et al., 2011), (Hallelujah 2009), (Natural herbs used in treatment of
cancer., livestrong_com)
SCIENTIFIC REVIEW
 Arun kumar R et al., 2010 investigated the anti-hyperlipidemic and
hypoglycemic activities of methanol leaf extract of Wattakaka volubilis in
alloxaninduced diabetic rats. The extract was administered at doses of 50,
100, and 200 mg/kg and glibenclamide was administered at a dose of 5mg/kg
for 28 days to animals with alloxan-induced diabetes. Serum glucose and
lipid profiles were determined on days 7, 14, 21, and 28. At the end of 28
days, the oral administration of a graded dose (200mg/kg) of Wattakaka
volubilis produced a significant reduction in serum glucose, total cholesterol,
triglyceride, LDL, and VLDL levels and an increase in HDL levels from the
regulation of insulin secretion and islet protection compared with diabetic
control rats. An acute toxicity study was observed in plant extracts that did
not reveal any behavioral changes or mortality even at a dose of 1000mg/kg.
The present study suggests that W. volubilis leaves show significant anti-
hyperlipidemic and hypoglycemic activities in diabetic rats.
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 Nandi et al.,2011 investigated to possess medicinal effects. In the present
study, the dried leaf extract [methanol–water (1:1)] of W. volubilis
designated as ‘the extract’ was evaluated for pharmacological activity in rats
and mice. The anti-inflammatory activity was evaluated  using acute, sub-
chronic and chronic models of inflammation in rodents. The antipyretic and
analgesic activities were evaluated in mice models. In the acute toxicity
study, it was found that  the extract was non-toxic up to 1 g/kg, i.p. The
extract (50, 100 and 200 mg/kg, i.p.) was found to possess, anti-
inflammatory, analgesic and antipyretic activities in a dose dependent
manner and the effect was comparable with the standard drug,ibuprofen.The
extract significantly inhibited the arachidonic acid-induced  paw oedema in
rats, indicating that the extract inhibited both the cyclo-oxygenase and lipo-
oxygenase pathways of arachidonic acid metabolism. The extract also
significantly enhanced the macrophage count in mice in a dose- and time-
dependent manner. It is possible that the saponins present in the extract may
be responsible for these activities.
 Maruthupandian A et al.,2010 investigated for its antidiabetic effect in
Wistar Albino rats. Diabetes was induced in Albino rats by administration of
alloxan monohydrate (150mg/kg, i.p). The ethanol extract of Wattakaka
volubilis at a dose of 150mg/kg of body weight was administered at single
dose per day to diabetes induced rats for a period of 14 days. The effect of
ethanol extract of Wattakaka volubilis leaf extract on blood glucose, plasma
insulin, glycosylated haemoglobin, serum lipid profile [total cholesterol,
triglycerides, low density lipoprotein - cholesterol (LDL-C), very low density
lipoprotein - cholesterol (VLDL-C), and high density lipoprotein- cholesterol
(HDL-C) serum protein, albumin, globulin, A/G ratio, serum enzymes
[Serum glutamate pyruvate transaminases (SGPT), serum glutamate
oxaloacetate transaminases (SGOT) and alkaline phosphatase (ALP)],
lipoprotein peroxidation (LPO) antioxidant enzymes (catalase (CAT),
superoxide dismutase (SOD), reduced glutathione (GSH) ,glutathione
peroxidase (GPx) and glutathione reductase (GR) were measured in the
diabetic rats. The ethanol extract of Wattakaka volubilis leaf elicited
significant reductions of blood glucose (p<0.01), lipid parameters except
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HDL-C, serum enzymes and significantly increased HDL-C and antioxidant
enzymes. The extracts also caused significant increase in plasma insulin
(p<0.01) in the diabetic rats. From the above results it is concluded that
ethanol extract of Wattakaka volubilis possesses significant antidiabetic,
antihyperlipidaemic and antioxidant effects in alloxan induced diabetic rats.
 Madhavan V et al., 2010 investigated In the present study two botanical
sources of Murva, viz. Wattakaka volubilis and Maerua oblongifolia, were
tested for antipyretic activity by yeast-induced pyrexia in Wistar albino rats.
Alcohol and aqueous extracts of both species significantly reduced the
elevated rectal temperature in febrile rats within 30 min of their
administration. The results of these studies support the traditional use of
these two botanical sources of the drug Murva in the treatment of fever.
 Moulisha Biswas et al.,2010 has investigated the use of petroleum ether
extract of Dregea volublis fruits (PEDV) for antitumour effect in Ehrlich
Ascitis Carcinoma (EAC) bearing swiss albino mice. 24 h after
intraperitonial inoculation of tumour (EAC) cells in mice, PEDV extract was
administered at 100 and 200 mg/kg body weight for 9 consecutive days. On
10th day half of the mice were sacrificed and rest were kept alive for
assessment of increase in life span. The antitumour effect of PEDV was
assessed by tumour volume,tumour weight,viable and non-viable cell
count,median survival time and increase in life span of EAC bearing hosts.
Haematological profiles were investigated. PEDV showed significant (p<
0.001) decrease in tumour volume,tumour weight,viable cell count and
increase in life span of EAC bearing mice. Haematological profiles were
significantly (p<0.001) restored to normal levels in PEDV treated mice as
compare to EAC control. Therefore from the present study it can be
concluded that Dregea volubilis exhibit remarkable antitumour activity
against Ehrlich Ascitis Carcinoma (EAC) in swiss mice.
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 Divya T S et al,2009 investigated for its anti-inflammatory and analgesic
effects in animals. The extract showed a significant inhibition of
carrageenan-induced rat paw edema and acetic acid-induced writhing in mice
compared to the standard anti-inflammatory and analgesic drug,
indomethacin. The extract also showed potent in vitro inhibition of FeCl2-
ascorbic acid-stimulated mice liver lipid peroxidation.
 Biswas M et al,2009 investigated for analgesic activity in swiss albino mice
by inducing writhing reflex with acetic acid. The petroleum ether extract of
the fruits of Dregea volubilisBenth led to isolation of a pentacyclic
triterpenoid designated as taraxerol and characterized as D- friedoolean- 14-
en, 3 ol [Figure 1]. In vitro analgesic activity has been shown by the isolated
taraxerol. The compound taraxerol obtained from the petroleum ether extract
of the fruits ofDregea volubilis showed analgesic activity in swiss albino
mice.
 Emdad Hossain et al.,2010 investigated for anti-inflammatory activity of
methanolic extract of Wattakaka volubilis leaves with it’s fractions and to
declineate the possible mechanism of action for MEDV. The anti-
inflammatory activity of MEDV alongwith it’s petroleum ether and
chloroform extract is evaluated in a carrageenan induced model for acute
inflammation. The effect of MEDV on lipopolysacchariedes induced NO
production was also studied. MEDV ( 100,200 and 400 mg/kg body weight )
significantly reduced carrageenan induced paw edema,chloroform fraction
was most potent (66%, p <  0.001). MEDV was non-toxic up to 125
microgram/ml in mice peritoneal macrophages wherein it (0-100
microgram/ml) reduce liposacchariedes induced NO production. Thus
MEDV possesses significant anti-inflamatory. Chloroform extract of MEDV
showed best anti-inflammatory activity.
 Shukla Amit Kumar et al.,2011 investigated to possess medicinal effects.
In the present study, the dried root ethanol extract of W. volubilis designated
as 'the extract' was evaluated for pharmacological activity in rats and mice.
The anti-inflammatory and antipyretic activities were evaluated in rodents.
The analgesic activity was evaluated in mice models. In the acute toxicity
study, it was found that the extract was non-toxic up to 1 g/kg, p. o. The
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extract (100, 200 and 300 mg/kg, p. o.) was found to possess, anti-
inflammatory, analgesic and antipyretic activities in a dose-dependent
manner and the effect was comparable with that produced by the standard
drug, ibuprofen. The extract significantly inhibited the arachidonic acid-
induced paw oedema in rats, indicating that the extract inhibited both the
cyclo-oxygenase and lipo-oxygenase pathways of arachidonic acid
metabolism.
 Jeyachandran R et al.,2010 investigate the qualitative phytochemicals and
antimicrobial properties of different solvent crude extracts of four Indian
medicinal plants namely, Nerium oleander, Lippia nodiflora, Wattakaka
volubilis and Wrightia tinctoria against various bacterial pathogens. The
presence of steroids, triterpenoids, phenolic compounds, tannins, alkaloids,
saponins, flavanoids and reducing sugars was indicated by the tests
conducted. The plant extracts showed different diameters of inhibition zone
ranging between 4 to 28 mm. Among themselves, methanol, ethyl acetate,
hexane and petroleum ether extracts of N. oleander exhibited the highest
inhibition zone against S. typhi. The in vitro antibacterial assay and
preliminary phytochemical analysis may open way for complementary future
investigations in identifying potentially useful properties of chemical and
pharmacological importance
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3. AIM AND OBJECTIVE
The main aim of the study is to evaluate the anti cancer activity of ethanolic
extract of Wattakaka volubilis leaves on DAL induced lymphoma in mice.
Cancer is one of the dangerous, lethal and a major challenging disease to
public health. To produce more potent and the site specific anti-neoplastic drugs,
vast number investigations are going on to find out the potent and safer new anti-
neoplastic drugs.
Most of the synthetic anti-neoplastic agents produce undesirable side effects.
On the other side the plant sources are available as a potent and safer alternative for
cancer treatment than compared to synthetic drugs. Thereby in the current study,
natural plant source was selected rather than a synthetic drug. The drug is also
cheaper than synthetic drugs. Being a natural herb the side effects may also be lesser
than the synthetic drugs.
Wattakaka volubilis has large amounts of flavanoids, phytosterol compounds
and many other active chemical constituents. (Preliminary phytochemical studies)
Flavanoids have a capacity to elevate the antioxidant levels and prevent the
free radical reactions and it is also reported that flavanoids have an anti-cancer
activity. Flavanoids are also called as free radical scavengers because of their
activity on the free radicals and ROS. Hence the present study of Wattakaka
volubilis leaves which have high amount of flavanoids content was choosen for
evaluating the anti-cancer activity due to its free radical scavenging properties; since
many studies done previously on flavanoid for antioxidant and anti-cancer activities.
(Gupta M et al., 2004).
The study was also supported by the anti-tumour effect of fruits of Dregea
volubilis (Moulisha Biswas et al.,2010).
Thus the present study was choosen with an objective of anticancer activity
of ethanolic extract of Wattakaka volubilis leaves on DAL induced lymphoma in
mice with it’s antioxidant effect.
Chapter – 4 Plan of Work for the Study
Dept. of Pharmacology 41 JKK Nattraja College of Pharmacy
4. PLAN OF WORK FOR THE STUDY
1. Collecting the plant material .
2. Authentication for the plant specimen.
3. Drying of  the leaves of the plant in shade and ground to a coarse powder.
4. Extraction by soxhlet extractor.
5. Acute toxicity studies of the extract.
6. Preliminary phytochemical studies of the extract.
7. Quantitative estimation of extract obtained.
8. Evaluation of in-vitro antioxidant effect.
9. In-vivo anti-cancer activity.
a) Mean survival time and body weight
b) Parameters
10. In-vivo antioxidant activity
11. Results of in-vitro and in-vivo studies.
12. Interpretation of the results.
13. Discussion.
14. Conclusion.
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5. MATERIALS AND METHODS
5.1. COLLECTION OF PLANT AND AUTHENTICATION
The leaves of Wattakaka volubilis was collected personally from forest
reserve area, kolli hills, Dt. Namakkal,Tamilnadu and was authentified by Dr. G. V.
S. Murthy, Scientist ‘F’ & Head of Office, Botanical Survey of India, Southern
Regional Centre, Coimbatore. (Ref. No. – BSI/SRC/5/23/2011-12/Tech.-844)
1). EXTRACTION OF LEAVES
The leaves of Wattakaka volubilis were collected and dried in shade for
about a week until they were completely dried and powdered to a coarse powder.
(Sieve No.- 40). Then the powder was extracted in petroleum ether using soxhlet
apparatus for 30 hours at a temperature of 40-60° C to remove all of the fatty
materials. Then the coarse powder was again dried and extracted using ethanol for
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72hours at a temperature of 50° C. Then the extract was distilled to remove the
excess of solvent using a simple distillation apparatus and concentrated.
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5.2. PRELIMINARY PHYTOCHEMICAL TESTS OF ETHANOLIC
EXTRACT OF Wattakaka volubilis
A) Test for carbohydrates
1) Molisch Test
A small amount of methanolic extract was treated with -naphthol
and concentrated sulphuric acid was added along the sides of the test tube. Purple
colour or reddish violet colours obtained at the junction between two liquids
indicates the presence of carbohydrates.
2) Fehling’s Test
In this a small amount of extract was treated with equal quantity of
Fehling’s solution A and B is and heat gently in a water bath for few minutes, brick
red precipitate was obtained which indicates the presence of carbohydrates.
3) Benedict’s test
To 5 ml of Benedict’s reagent, added 8 drops of extraction solution
and mixed well, and boiled the mixture vigorously for two minutes and then cooled.
Red precipitate indicates the presence of carbohydrates.
4) Barfoed’s test
To the 5 ml of the Barfoed’s solution added 0.5 ml of extract solution
and mixed well and heated to boiling, red precipitate indicates the presence of
carbohydrates.
B) Test for Alkaloids
About 2 ml of the extract was boiled for five minutes on a water bath
with 10 ml of 10% hydrochloric acid. The  extract was  filtered  and  the pH of  the
filtrate was adjusted  to about 6 by adding a  few drops of dilute ammonia  solution
and  tested with  litmus paper.
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Then to the filtrate was added with few  drops of Dragendroff’s,
Mayer’s  and Wagner’s  reagent separately in  the  test  tubes.  A reddish brown,
cream and reddish brown precipitate indicates the presence of alkaloids.
C) Test for Steroids and Sterols
1) Libermann Burchard test
The extract was dissolved in 2 ml of chloroform in a dry test tube
and added 10 drops of acetic anhydride and 2 drops of concentrated sulphuric acid.
The solution becomes red, which later was changes to blue and bluish green color
indicates presence of steroids and sterols.
2) Salkowski test
Extract was dissolved in chloroform and added equal volume of conc.
sulphuric acid. A bluish red cherry red and purple color in chloroform layer, and
also green fluorescence indicates the presence of steroids and sterols.
D) Test for Glycosides
1) Legal’s test
The extract was dissolved in pyridine sodium nitropruside solution
and made alkaline. Pink or red color indicates the presence of glycosides.
2) Baljet test
The extract was added with, sodium picrate solution and Yellow to
orange colour shows the presence of glycosides.
3) Borntrager test
A few ml of dilute sulphuric acid added to the extract solution,
boiled, filtered and extracted the filtrate with ether or chloroform. The organic layer
was removed to which ammonia was added. Pink, red or violet colour in organic
layer shows the presence of glycosides.
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4) Keller Killiani test
The extract was dissolved in acetic acid containing traces of ferric
chloride and concentrated sulphuric acid was added. At the junction of liquid
reddish brown color was produced which gradually becomes blue indicates the
presence of glycosides.
E) Test for Saponins
About one gram of the powdered sample was boiled with 10 ml of
distilled water for ten minutes. The samples were filtered while hot, cooled and the
following tests were carried out.
1) Frothing
2.5 ml of the filtrate was shaken vigorously for 2 minutes with water. If any
frothing was observed it indicates the test was positive.
2) Emulsification
2.5ml of the filtrate was shaken vigorously with a few drops of olive oil. If
an emulsified layer obtained indicates a positive test.
F) Test for Flavanoids
A  small  quantity of  the  extract added with dilute sodium  hydroxide  and
hydrochloric acid was also added. A yellow solution that turns colorless on addition
of hydrochloric acid indicates the presence of flavonoids.
G) Test for Triterpenoid
In the test tube, 2 or 3 granules of tin was added, and dissolved in a 2ml of
thionyl chloride solution and test solution was added. If any pink color was
produced it indicates the presence of Triterpenoid.
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H) Test for Protein and Amino acid
1) Biuret test
To the extract added 1 ml of 40% sodium hydroxide and 2 drops of 1%
copper sulphate, if any violet color it indicates the presence of proteins.
2) Ninhydrin test:
Added 2 drops of freshly prepared 0.2% ninhydrin reagent to the extract and
heated. A blue color indicates the presence of proteins, peptides or amino acids.
3).Xanthoprotein test
The extract, was added with 20% of sodium hydroxide any orange color
produced indicates presence of aromatic amino acid.
I). Phenols and tannins
100 mg of extract was boiled with 1 ml of distilled water and filtered. The filterate
was used for the test
1). Ferric chloride test
To 2 ml of filtrate, 2 ml of 1% ferric chloride was added in a test tube. The
formation of bluish black color indicates the presence of phenolic nucleus.
2). Lead acetate test
To 2 ml of filtrate few drops of lead acetate solution was added in a test tube.
Formation of yellow precipitate indicates the presence of tannins. (Khandelwal,
2004)
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5.3. DETERMINATION OF TOTAL PHENOLS
Total soluble phenolic content of the extract was determined by using the
Folin-Ciocalteu reagent and the values are expressed as equivalents of gallic acid.
An aliquot (1 ml) of extract or standard solution of Gallic acid (20, 40, 60, 80 and
100 μg/ml) were mixed with 0.2 ml of Folin-Ciocalteu reagent.
After 5 min, 1 ml of 15% Na2CO3 solution and 2 ml of distilled water were
added to the above mixture. A blank solution using distilled water was prepared.
After incubation for 90 min at room temperature, the absorbance of the mixture was
measured against blank at 750 nm.  Samples were analyzed in triplicate and mean of
three readings was used and the total phenolic contents were expressed as
milligrams of Gallic equivalents per gram extract. (Sreeramulu and Raghunath,
2010), (Padma et al., 2011)
5.4. DETERMINATION OF ACUTE ORAL TOXICITY (LD50) OF
ETHANOLIC EXTRACT OF Wattakaka volubilis
Table-1 Test substance details
Name of the test substance
Ethanolic extract of Wattakaka volubilis
leaves
Color Greenish black
Nature of the test substance Liquid
Table – 2 Experiment protocol
Name of the study Acute toxicity
Guideline followed
OECD 425 method-acute toxic class
method
Animals
Healthy young adult Swiss albino mice,
non-pregnant
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Body weight 25-30 grm
Sex Male
Administration of dose and volume
2000,550,1000 mg/kg body weight,
single dose in 0.2ml
Number of animals 3 animals
Route of administration Oral (by using mice oral feeding tube)
Vehicle Carboxy methyl cellulose (CMC)
Table – 3 Housing and feeding conditions
Room temperature 22 ±  3°C
Humidity 40-60%
Light 12 hr light/12 hr dark cycle
Feed
Standard laboratory animal food pellets
with water ad libitum
Table -4 Study period and observation parameters
Initial once observation First 30 minutes
Special attention First 1-4 h after drug administration
Long term observation Up to 14 days
Direct observation parameters
Diarrhoea, sitting in the corners, sniffing
excessively, standing on hind limbs
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Additional observation parameters
Skin, fur, eyes and mucous membrane,
respiratory, circulatory, autonomic and
central nervous systems, somatomotor
activity and behavior pattern etc.
If any death of animal was found it was recorded.
Study procedure
Acute oral toxicity was performed as per organization for economic co-
operation for development (OECD) guideline 425 methods. The extract was
administered in a single dose by gavages using specially designed mice oral needle.
Animals were fasted 24h prior to dosing (water ad libitum). (OECD Guideline for
testing of chemicals 425)
5.5. ESTIMATION OF INVITRO ANTIOXIDANT ACTIVITY OF
ETHANOLIC EXTRACTS OF Wattakaka volubilis (L).
1). DPPH PHOTOMETRIC ASSAY:
AA % = 100 - { [(ABS SAMPLE – ABS BLANK) X 100 ] / ABS CONTROL}
DPPH radical scavenging activity was determined based on the ability of the
antioxidant to scavenge the DPPH cation radical. Briefly, 100µl of sample extract or
standard was added to 2.9 ml of DPPH reagent (0.1 mM in ethanol) and shaken
vigorously. It was incubated in dark for 30 min at room temperature and the
discoloration of DPPH was measured against blank at 517 nm. Percentage inhibition
of the discoloration of DPPH by the sample extract was expressed as trolox
equivalents.
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2). FERRIC REDUCING ABILITY OF PLASMA (FRAP) EXPRESSED AS A
FUNCTION OF TIME:
Absorbance = 0.274 x M of Fe++ + 0.114 [R2 = 0.974]
Ferric reducing antioxidant power (FRAP) was determined in sample extract
according to method which was based on the ability of the sample to reduce Fe3+ to
Fe2+ions.
In the presence of TPTZ the Fe2+- TPTZ complex exhibits blue color which
is read at 593 nm. Briefly, 3 ml of working FRAP reagent was added to the
appropriate concentration of sample extract. After incubation for 6 min at room
temperature the absorbance was measured at 593 nm against Ferrous sulphate as
standard. (Ratnesh K Sharma et al., 2009), (Sreeramulu and Raghunath, 2010)
3). ABTS RADICAL SCAVENGING ASSAY
Scavenging of 2, 2-azino-bis (3-ethylbenzo-thiazoline-6-sulfonic acid)
Diammonium salt (ABTS) radical cation
ABTS+ radical was freshly prepared by adding 5 ml of 4.9 mM ammonium
per sulfate solution to 5 ml of 14 mM ABTS solution and kept for 16 h in dark. This
solution was diluted with ethanol (99.5%) to yield an absorbance of 0.70±0.02 at
734 nm (0.05 ml taken and added with 2.9 ml) and the same was used for the assay.
950 μl of above adjusted ABTS radical solution was, taken and to it added
about 50 μl of extract solutions (20, 40, 60, 80 and100μl) and the reaction mixture
was vortexed for 10 sec. After 6 minutes the absorbance was recorded at 734 nm.
Percentage inhibition was calculated from the formula.
(Satish kumar et al., 2008)
Percentage inhibition= [1−(absorbance of test/absorbance of control)]×100
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4). DCF/AAPH ASSAY (TRAP)
An azo initiator, AAPH, was used to produce peroxyl radicals, and the
scavenging activity of ethanolic extract was monitored via the spectrophotometric
analysis of 2, 7- dichlorofluorescin diacetate (DCF).
The activation of DCF was achieved by mixing 350 µl DCF (1mM in
methanol) and NaOH (1.75 ml of 0.01N solution) and allowing the mixture to stand
for 20 min before adding 18.25 ml of sodium phosphate buffer (25 mM, pH 7.2).
From the above reaction mixture 150μl solution was taken and 500 µl of
sample taken in different concentration (20, 40, 60, 80 and 100μl) and made up to
volume. To this solution added 25 µl of 600 mM AAPH (2- amidino proponic
dihydro chloride, adjusted to a final concentration of 56 mM).
The reaction was initiated by adding the AAPH solution. After 10 min, the
absorbance was read at 490 nm using a Specrophotometer. (Yong cui et al., 2005)
5) SUPER OXIDE SCAVENGING ABILITY
Nitro blue tetrazolium (NBT) (156 μM, NBT in 100 ml phosphate buffer pH
7.4) mixed well with 1ml of NADH (468 μM in 100mM of phosphate buffer pH
7.4). To this mixture added sample in different concentrations (20, 40, 60, 80 and
100 μl) and adjusted the volume to 100 μl and added 100 μl of PMS (phenazine
metro sulphate 60 μM PMS in 100 μM of phosphate buffer).
Incubated the mixture for 5 min at 25o C and the absorbance was measured at
560 nm.
6). NITRIC OXIDE SCAVENGING ABILITY
About 4 ml of sample solution at different concentrations (20, 40, 60, 80 and
100 μl) was taken and to this added 1 ml of sodium nitoprusside solution (5 mM)
and incubated well for 2 hrs at 25oC.
After 2 hrs the 2 ml of the above mixture solution was taken and mixed with
1.2ml of griess reagent( 1% sulphanilamide + 5% of 0.1% napthyl ethylene diamine
hydrochloride + phosphoric acid) and absorbace measured at 550 nm.
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5.6. EVALUATION OF IN VIVO ANTICANCER ACTIVITY
Animals used
Inbred male or female Swiss albino mice of 2 months age, weighing 25 ± 5
grm, were used for the study. They were housed at room temperature of 22o C under
12 hr light/12 hr dark cycle in the animal house. Mice were fed with commercial
pellet diet and water ad libitum throughout the study. All animal procedures were
performed after approval from the IAEC (institution of animal ethical committee)
and in accordance with the recommendations for the proper care and use of
laboratory animals. (Proposal No- 25MP15JUN11)
5.7.1. DAL-INDUCED ASCITIC ANTITUMOR MODEL
1). Adjust Cell Count
0.5 ml of 0.4% Tryphan blue, 0.3 ml of PBS and 0.2 ml of cell suspension
were mixed and kept aside for 5 min and not more than 15 min. From this one drop
of solution was taken on a neubar chamber and a cover slip was placed. This is
placed on microscope and the viable, non-viable cells were counted using 10x power
lens. Viable cells do not take color and appear white in color on blue background.
Nonviable cells (dead cells) take blue color and give dark blue shading to the cells.
The cell count was calculated using formula.
Cell count = No. of cells x Dilution factor × volume factor. (Talwar, 1974)
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Chart-1 The chart shows the doses to different groups of animals (5-FU and
Extract) which were fixed based on earlier works done on DAL. (International
journal of health research 2008; 1(2): 79). The various parameters were also
performed which were explained in detail below:
SYSTEMATIC SCHEME
OF WORK
Ethanolic Extract Of Wattakaka
volubilis on Dalton’s ascites
lymphoma tumor cell lines (DAL)
METHOD-I
DAL-INDUCED ASCITIC TUMOR IN MICE
1×106Cells/mouse(i.p)
I. Determination
of mean survival time & body
weight (each group contain 6 mice)
GROUP-I
DAL ONLY
GROUP-II DAL+5-FU 20mg/kg(i.p)
GROUP-III DAL+EXTRACT
100mg/kg(p.o)
GROUP-IV DAL+EXTRACT
200mg/kg(p.o)
1. Body weight analysis
2. Determination of mean
survival time (MST)
2. Determination of
various parameters
(each group contain 6 mice)
GROUP-V
NORMAL MOUSE
GROUP-VI
DAL ONLY
GROUP-VII
DAL+5-FU20mg/kg(i.p)
GROUP-VII DAL+ EXTRACT
100mg/kg(p.o)
GROUP-IX DAL+ EXTRACT
200mg/kg(p.o)
3.Tumor volume
4. Viable and Non-viable cell
count
5. Hematological  parameters
6. Biochemical parameters
7. Invivo anti oxidant studies
8.Histological observation
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2). DAL-induced ascitic antitumor model:
The anti tumor activity of the ethanolic extract was determined by injecting
DAL cell suspension (1×106 cells per mouse) in to the peritoneal cavity of the
animals. The treatment was started after 24 hours of the tumor inoculation and
continued once daily for 14 days and the antitumor efficacy of extract was compared
with that of standard drug 5-FU (20mg/kg, i.p) and DAL control.
5.7.2. DETERMINATION OF BODY WEIGHT AND SURVIVAL TIME
1). Body weight analysis:
All the mice were weighed for every seven days, after tumour inoculation.
The average gain in body weight was determined and recorded and a % decrease in
body weight was calculated by the formula.
Decrease in body weight
% Decrease in body weight = ----------------------------------- X 100
Initial body weight
2). Mean Survival Time (MST):
After induction of the tumour, every day all the groups were checked for
mortality & recorded. The no. days each mouse survived was noted. The mean
survival time (MST) and percentage increase in life span (ILS %) was calculated by
the formula.
1st Death + Last Death
Mean survival time = -----------------------------
2
Mean survival of treated group
ILS (%) = ----------------------------------------- -1   X 100
Mean survival of control group
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5.7.3. DETERMINATION OF VARIOUS OTHER PARAMETERS
1). Determination of tumor volume
All the mice in this group were inoculated with tumour cells and the drug
given after 24 hrs of inoculation. Treatment continued for 14 days and after14 days
treatment the mice were dissected by anaesthetizing using diethyl ether and the
ascitic fluid was collected from the peritoneal cavity. The volume was measured by
taking it in a graduated centrifuge tube.
2). Viable and nonviable cell count
After 14 days of treatment animals were anaesthetized with diethyl ether.
Then from the intraperitonial cavity 0.2 ml of cell suspension was aspirated out
using a syringe and was mixed with 0.5 ml of 0.4% tryphan blue, 0.3 ml of normal
saline or PBS and kept aside for 5 min and not more than 15 min. From this one
drop of solution was taken on a neubar chamber and a cover slip was placed on the
solution. The chamber was placed on a microscope and the viable, nonviable cells
were counted under 10x power lens. Viable cells appear white in colour on blue
background and nonviable cells (dead cells) take blue colour and give dark blue
shading to the cells. The cell count was calculated using formula .
Cell count = No. of cells x Dilution factor × volume factor
Preparation of Blood Serum and Tissue Samples for Bio Chemical Studies
After 14 days of treatment the animals were fasted over night and
anesthetized using diethyl ether. The blood sample was collected from eye (retro
orbital bleeding) to maximum using a capillary tube. Then animal sacrificed by
cervical dislocation and the intraperitonial fluid was taken and measured.
Blood was collected for estimation of hematological parameters (RBC,
WBC, Differential cell count , Hb percentage, MCV, MCHC, Hematocrit, MCH,
platelet count) and serum was separated from blood cells by centrifugation at about
2000 rpm for 30 min and used for estimation of different biochemical parameters
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(SGOT, SGPT, Serum creatinine, serum triglycerides, alkaline phosphatase,
albumin, total protein values.)
The mice were dissected after collecting the blood and the liver was
removed. The blood and other body fluids were cleaned using a blotting paper and
then cleaned in normal saline and transferred to ice cooled containers with 10%
formalin solution.(histopathological studies). Some tissues were cleaned with
normal saline and again wiped and were used for other parameters (In-vivo
antioxidants).
5.7.4. ESTIMATION OF HAEMATOLOGICAL PARAMETERS
1). Enumeration of white blood cells
The total white blood cells were enumerated according to the method of John
(1972) using Turk’s fluid (WBC diluting fluid).
Using a white blood cell pipette of haemocytometer, blood was drawn up to
0.5 mark and WBC diluting fluid was taken up to mark II. The blood mixture was
shaken and transferred onto the counting chamber (neubar chamber) and the cells
were allowed to settle for 2 min the fluid should not get dried.
Using 10x objective the WBC’s were counted uniformly in four larger corner
squares. The cells were expressed as number of cells x109/L. (John, 1972)
2). Enumeration of red blood cells
Using a red blood cell pipette of haemocytometer, blood was drawn up to 0.5
mark and RBC diluting fluid was taken up to mark II. The mixture was shaken and
transferred onto the counting chamber (neubar chamber). The cells were allowed to
settle for 2 min the fluid does not get dried. Using 45x objective the RBC’s were
counted uniformly in the smaller 4 corner squares.  The cells were expressed as
number of cells x1012/L or in x 106 / cu.mm. (Text book of medicinal lab
technology, 2007)
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3). Differential Leukocyte Count
Differential Leukocyte count was determined by the method of John (1972).
Leishmann’s stain 150 mg of powdered leishmann’s stain was dissolved in 133 ml
of acetone free methanol.
A blood film stained with leishmann’s stain and examined under oil
immersion lens and the different types of WBCs were identified. The percentage
distribution of these cells was then determined. Smears were made from
anticoagulant blood specimens and stained with leishmann’s stain. The slides were
preserved for counting the number of lymphocytes and neutrophils, per 100 cells
were noted. The number of neutrophils was expressed as (%). (John 1972)
4). Estimation of Haemoglobin:
Haemoglobin was converted into acid haematin by the action of dilute
hydrochloric acid. The acid haematin solution is further diluted with distilled water
until its colour matches exactly with that of permanent standard. The Hb
concentration is read directly from the calibration tube by comparing the color with
the standard in the stand.
By using pipette 0.1 N HCl was taken up to the lowest marking in the
Haemoglobinometer and blood was drawn up to 20µl in the sahli’s pipette. The
excess of blood on the sides of the pipette was cleaned by using a dry piece of
cotton. Blown the blood into the acid solution in the graduated tube, rinsed the
pipette well and stirred well to remove if air bubbles present. Mixed the solution and
allowed the mixture to stand at room temperature for 10 minutes. The solution was
then diluted using distilled water. Water was carefully added drop by drop and
stirred until the color matches with that in the comparator in the
haemoglobinometer. The lower meniscus of the fluid was noted and reading was
noted in g/100ml. (Sahli’s acid hematin method)
The haematological paramaeters like MCH, MCV, MCHC, Hematocrit, and
Differential leukocytes were measured using automated method using instrument-
celldyn 1700 haematology analyzer (3 part).
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5.7.5. ESTIMATION OF SERUM BIOCHEMICAL PARAMETERS
SGOT, creatinine, triglycerides, albumin, total Protein, ALP etc were estimated
using blood serum which was separated from blood by centrifuging at 10,000 rpm
for 10 min and the supernatant solution taken and all the above biochemical
parameters were performed which were estimated using semi-auto analyzer
(Photometer 5010 V5+) with enzymatic kits.
1). Estimation of SGOT (Serum   glutamic oxaloacetic transaminase):
Alanine aminotransferase (ALAT) and aspartate amino transferase (ASAT)
are the most important group of enzymes of aminotransferase. These enzymes act as
catalyst in conversion of α-keto acids in to amino acids.
Increased levels of  ALAT is found in the hepatobillary disease condition
where as increased ASAT levels occur in damaged conditions of heart and skeletal
muscles well as liver parenchyma. Parallel measurement of ALAT and ASAT is
therefore applied to distinguish liver from heart or skeletal muscle damages.
The ASAT/ALAT ratio is used from differential diagnosis of liver diseases
L-Aspartate + 2-Oxaloglutarate ASAT L-Glutamate + oxaloacetate
Oxaloacetate + NADH + H⁺ MDH D-Malate + NAD⁺
Optimized UV- test used according to IFCC (International Federation of
Clinical Chemistry and Laboratory Medicine).
Table- 5 Reagents of SGOT kit
Reagent-1 Concentration
TRIS buffer     pH 7.8 80 mmol/l
L- Aspartate 240 mmol/l
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MDH (malate dehydrogenase) ≥ 600 U/l
LDH (lactate dehydrogenase) ≥ 600 U/l
Reagent-2 Concentration
2-Oxaloglutarate 12 mmol
NADH 0.18 mmol
Good’s Buffer      pH   9.6 0.7 mmol/l
Pyridoxal-5-Phosphate 0.09 mmol/l
Assay procedure:
a) Mixed 800 µl of reagent-1 with 200 µl of reagent-2 in a 5 ml test tube.
b) To this, added 100 µl of serum.
c) Mixed well and took the absorbance measured immediately in the
photometer and values were noted.
Normal range : < 37 μ/l
2).Estimation of Creatinine:
Creatinine levels were estimated by modified Jaffe Method. Creatinine forms
a colored complex with picrate in alkaline medium. This rate of formation is
measured.
Chapter – 5 Materials and Methods
Dept. of Pharmacology 61 JKK Nattraja College of Pharmacy
Table - 7 Reagents of creatinine kit
Reagent 1 Standard creatinine (2 mg/100 ml)
Reagent 2 Picric acid solution
Reagent 3 Sodium hydroxide solution
500 μl of reagent-2 and 500 μl of reagent-3 were taken in a 5ml test tube. To
this added 100 μl of serum and mixed well and read the sample in photometer.
Normal range: 0.6 -1.1 mg/dl.
3).Triglycerides
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein
lipase. Quinoneimine used as an indicator which is generated from 4-
aminoantipyrine and 4- chlorophenol by hydrogen peroxidase under the catalytic
action of peroxidase.
Triglycerides LPL Glycerol + fatty acid
Glycerol + ATP GK Glycerol-3-phosphate+
ADP
Glycerol-3-phosphate +O2 GPO Dihydroxyaceton phosphate +
H2O2
2H2O2 + 4- Amino antipyrine + 4- chlorophenol POD Quinonelimine +
HCL +
4H2O2
Colorimetric enzymatic test performed using glycerol-3-phosphate-oxidase
(GPO).
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Table- 8 Reagents of Triglycerides in the kit
4-chloroPhenol 4 mmol/l
ATP 2 mmol/l
Mg2+ 15 mmol/l
Glycerokinase > 0.4 Kµ/l
Peroxidase > 2 Kµ/l
Lipoprotein lipase > 4 Kµ/l
4-aminoantipyrine 0.5 mmol/l
Glcerol-3-phosphate- oxidase > 1.5Kµ/l
Standard (2.3 mmol/l)
Good’s buffer pH 7.2, 50 mmol/ l
Assay procedure:
a) 1 ml (1000 µl) of reagent-1 was taken in a 5 ml test tube.
b) Added 0.01 ml (10 µl) of serum.
c) Mixed well and incubated at 37◦C   for 15 min.
d) Read the test sample under the photometer.
Normal Range: < 200 mg/dl (Cole T.G. et al., 1997)
4). Total protein
Protein forms a colored complex with cupric ions in alkaline medium
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Table- 9 Reagents of total protein in the kit
Reagent-1
Cupric sulphate(6 mmol/l)
Potassium iodide
(15 mmol/l)
Reagent-2 Protein (std) 6 g/100ml
Biuret method was followed for estimation
Preparation of test sample
1. Taken 1ml of reagent-1 in a5 ml test tube
2. To this added 0.02 ml of serum
3. Mix well and incubated at a room temperature for 15 min and Read the test
sample in photometer.
Normal range: 3.2 to 4.2 g/dl. (Weichselbaum, 1946)
5). Alkaline phosphatese
Alkaline phosphatase (ALP), and hydrolytic enzyme act optimally at an
alkaline pH. They are present in blood in numerous distinct forms which originate
mainly from bone and liver
p-Nitro phenyl phosphate +water ALP Phosphate + p-Nitro phenol
Kinetic photometric test, according to the international Federation of clinical
chemistry and laboratory Medicine (IFCC)
Table- 10 Reagents of Alkaline phosphatase in the kit
Reagent 1 : Concentration
2-Amino-2-methyl-1-propanol
pH 10.4
0.35 mol/l
Chapter – 5 Materials and Methods
Dept. of Pharmacology 64 JKK Nattraja College of Pharmacy
Magnesium sulphate 2.0 mmol/l
Zinc sulphate 1.0mmol/l
HEDTA 2.0 mmol/l
Reagent 2 : Concentration
p-Nitrophenylphosphate 16.0mmol/l
Assay method:
1. Taken 1000 µl of reagent-1 in a 5 ml test tube
2. To this added 250 µl of reagent-2 and mixed well
3. Add 20 µl of serum and mix well and take reading immediately using a
photometer.
Normal range: 53-128 μ/l. (Soldin et al., 1996)
6). Estimation of Serum Total cholesterol (TC)
Principle
Determination of cholesterol was done after enzymatic hydrolysis and
oxidation. The colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of
peroxidise (trinder’s reaction).
Cholesterol ester + H2 CHO Cholesterol + Fatty acid
Cholesterol + O2 CHO Cholesterol-3-one + H2O2
2H2O2 + Amino antipyrine + phenol POD Quinonelimine + 4H2O2
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Method
CHOD-PAP: enzymatic photometric test
Table- 11 Reagents of TC kit
goods buffer( pH 6.7) 50 mmol/I
Phenol 5 mmol/I
4-aminoantipyrine 0.3 mmol/I
Cholesterol esterase >200 U/I
Cholesterol oxidase >100U/I
Peroxidase 3 KU/I
Standard 5.2 mmol/I
Assay procedure
a. 1ml (1000 µl) of reagent-1 was taken in a 5ml test tube.
b. Added 0.01 ml (10 µl) of serum.
c. Mixed well and incubated at 370C for 5min.
d. Read the test sample in photometer.
Normal range: < 200 mg/dl
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5.7.6. IN VIVO ANTI OXIDANT STUDIES
Preparation of tissue homogenate
The tissues were weighed and 10% tissue homogenate was prepared using
phosphate buffer of pH 7.5. After centrifugation at 10,000 ×g for 10 min, the clear
supernatant was used to measure thiobarbituric acid reactive substances (TBARS).
(Yong cui et al., 2005)
A. Enzymatic antioxidant activity:-
1). Estimation of Superoxide Dismutase (SOD) activity
Reagents:
1. Adrenaline
2. Carbonate buffer (pH10.2),
3. 0.1Mm EDTA
The activity of superoxide dismutase (SOD) was assayed by the method
based on the oxidation of epinephrine adrenochrome transition by enzyme. The post-
mitochondrial suspension of mice liver (0.5 ml) was diluted with distilled water (0.5
ml).To this chilled ethanol (0.25 ml) and chloroform (0.15 ml) was added. The
mixture was shaken for 1 min and centrifuged at 2000 × g for 10 min.The PMS (0.5
ml) was added with PBS buffer (pH 7.2, 1.5ml). The reaction initiated by the
addition of epinephrine (0.4 ml) and change in optical density (O.D.,min-1) was
measured at 470 nm. SOD activity was expressed as U/mg of tissue. Change in O.D
(min-1) at 50% inhibition to adrenochrome transition by the enzyme was taken as
one enzyme unit. (Bito et al., 2008)
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2). Estimation of Catalase (CAT) activity
Reagents:
1. Dichromate/acetic acid reagent (5% solution of potassium dichromate in
acetic acid at 1:3 ratios)
2. 0.01 M Phosphate buffer, pH 7.0
3. 0.2 M Hydrogen peroxide
Catalase (CAT) was estimated by mixing 1.0 ml of 0.01 M phosphate
buffer (pH 7.0), 0.1 ml of tissue homogenate and 0.4 ml of 2 M hydrogen peroxide.
The reaction was stopped by the addition of 2.0 ml dichromate-acetic acid reagent
(5% potassium dichromate and glacial  acetic acid  were mixed in 1:3 ratio). Then
thebabsorbance was measured at 530 nm. CAT activity was expressed as µM of
H2O2 consumed/min/mg protein. (Sinha, 1972)
3). Estimation of Glutathione peroxidase (GPx) activity
Reagents:
1. 0.32 M Phosphate buffer, pH 7.0
2. 0.8 mM EDTA
3. 10 mM Sodium azide
4. 3 mM reduced glutathione
5. 2.5 mM H2O2
6. 10% TCA
7. 0.3 M Disodium hydrogen phosphate
8. DTNB solution (40 mg of DTNB in 100 ml of 1% sodium citrate)
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Procedure:
Glutathione peroxidase (GPx) was measured by mixing 0.2 ml 0.4 M
phosphate buffer (pH 7.0), 0.1 ml 10 mM sodium azide, 0.2 ml tissue homogenized
in 0.4 M phosphate buffer (Ph 7.0), 0.2ml reduced glutathione, and 0.1 ml 0.2 mM
hydrogen peroxide. The contents were incubated for 10 min at 37⁰ C, 0.4 ml 10%
TCA was added to stop the reaction and centrifuged at 3200 × g for 20 min.The
supernatant was assayed for glutathione content using Ellman’s  reagent (19.8 mg
5,5’-dithiobisnitrobenzoic acid (DTNB) in 100 ml 0.1% sodium nitrate). The
activities were expressed as µg of GSH consumed/ min/mg protein. ( Pridaran
Murugan, 2009)
B. Non enzymatic anti oxidant activity
1). Estimation of reduced glutathione(GSH) activity
Reagents:
1. 10% TCA
2 0.6 mM 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) in 0.2 M
sodium
phosphate
3. 0.2 M Phosphate buffer, pH 8.0
Reduced glutathione (GSH)  was measured by mixing PMS of rat liver (720 µl)
and 5% TCA to precipitate the protein content. After centrifugation at 10,000 × g for
5 min, the supernatant was taken. DTNB (5,5’-dithio-bis(2-nitrobenzoic acid )
Ellman’s reagent was added to it and the absorbance was measured at 412 nm. A
standard graph was drawn using different concentration of standard GSH solution.
GSH contents were calculated in the PMS of rat liver. (Brahma N Singh et al.,
2009)
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2). Estimation of Lipid Peroxidation
Reagents:
1. Thiobarbituric acid 0.37%
2.   0.25 N HCl
3 .15% TCA
Lipid peroxidation in liver was estimated calorimetrically by measuring
thiobarbituric acid reactive substances (TBARS). 0.1 ml of tissue homogenate was
treated with 2 ml of TBA- trichloroacetic acid– hydrochloric acid reagent (0.37%
TBA, 0.25 M hydrochloric acid and 15% TCA, 1:1:1 ratio), placed for 15 min in a
water bath and then cooled and centrifuged at 3500 ×g for 10 min at room
temperature, the absorbance of clear supernatant was measured at 535 nm against a
reference blank. Values were expressed as mM/100 g tissue. (Pridan Murugan et
al.,2009)
5.7.7. HISTOPHATOLOGICAL TECHINIQUES
Histopathology is the microscopical study of tissues for pathological
alterations. This involves collection of morbid tissues from biopsy or necropsy,
fixation, preparation of sections, staining and microscopical examination.
1). Collection of materials
Thin pieces of 3 to 5 mm, thickness were collected from tissues showing gross
morbid changes along with normal tissue.
2). Fixation:
Kept the tissue in fixative for 24-48 hours at room temperature
The fixation was useful in the following ways:
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a) Serves to harden the tissues by coagulating the cell protein,
b) Prevents autolysis,
c) Preserves the structure of the tissue, and
d) Prevents shrinkage
Common Fixatives: 10% Formalin
3). Haematoxylin and eosin method of staining:
Deparaffinise the section by xylol 5 to 10 minutes and remove xylol by
absolute alcohol. Then cleaned the section in tap water and stained with
haematoxylin for 3-4 minutes and again cleaned under tap water. Allow the sections
in tap water for few minutes and counter stained with 0.5% eosin until section
appears light pink (15 to 30seconds), and then washed in tap water. Blotted and
dehydrated in alcohol and cleared with xylol (15 to 30 seconds). Mounted on a
Canada balsam or DPX Moutant and kept the slide dry and remove air bubbles.
Chapter-6 Results and Discussion
Dept. of Pharmacology 71 JKK Nattraja College of Pharmacy
6. RESULTS AND DISCUSSION
6.1 Phytochemical Studies of Ethanolic Extract of Wattakaka volubilis Linn.
Preliminary Phytochemical Tests were performed using the ethanolic extract
and various results were obtained which were as follows
Table 12.
S.N. Phytochemical constituents Extract
1. Carbohydrates +ve
2. Alkaloids +ve
3. Steroids & sterols +ve
4. Glycosides +ve
5. Saponins +ve
6. Flavonoids +ve
7. Tannins +ve
8. Proteins & amino acids -ve
9. Phenols +ve
+ve – present -ve – absent
Inference- From the preliminary Phytochemical studies it was confirmed that the
ethanolic extract contains carbohydrates, alkaloids, steroids, glycosides, saponin,
tannins, flavanoids, phytosterols, and phenols as active chemical constituents.
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6.2. Determination of Total Phenols
Total phenol content of Ethanolic extract of Wattakaka volubilis Linn.
Table- 13
Sample Phenolic content( Gallic acid
equivalents mg/100g
Ethanolic Extract of Wattakaka
volubilis Linn
50.79±0.19
Data was expressed in fresh weight basis and is presented as mean ±SD. Data
subjected to statistical analysis (correlation between antioxidant activity and
phenolic content) using GraphPad Prism 5 statistical package. P< 0.03.
Inference – The presence of phenols in the extract shows that the extract has anti-
oxidant activity.
6.3. Toxicological evaluations of ethanolic extract of Wattakaka volubilis Linn:
Effect of ethanolic extract of Wattakaka volubilis on mice.
Table- 14
S.N
Response
Mice 1(4 hrs) Mice 2 (4 hrs) Mice 3 (4 hrs)
Before After Before After Before After
1 Alertness Normal Normal Normal Normal Normal Normal
2 Grooming Absent Absent Absent Absent Absent Absent
3 Anxiety Absent Absent Absent Absent Absent Absent
4 Roaming Normal Normal Normal Normal Normal Normal
5 Sniffing Normal Normal Normal Normal Normal Normal
6 Tremors Absent Absent Absent Absent Absent Absent
7 Convulsion Absent Absent Absent Absent Absent Absent
8 Depression Normal Present Normal Present Normal Present
9 Gripping strength Normal Normal Normal Normal Normal Normal
10 Scratching Present Present Present Present Present Present
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Result: From acute toxicity study it was observed that the administration of
ethanolic extract of Wattakaka volubilis Linn to mice did not cause any
toxicity of extract (4 hrs) and mortality in the animals (14 days) up to 1000
mg/kg orally.
6.4. INVITRO ANTI OXIDANT STUDY
1). DPPH Radical scavenging activity:
% inhibition of DPPH radical scavenging activity of Wattakaka volubilis extracts
Table- 15
Sample DPPH(Troloxequivalents)
Ethanolic extract of Wattakaka volubilis
Linn
50.20±1.21
Data was expressed in fresh weight basis and is presented as mean ±SD. Data
subjected to statistical analysis (correlation between antioxidant activity and
phenolic content) using GraphPad Prism 5 statistical package. P< 0.0001.
11 Defecation Absent Present Absent Present Absent Present
12 Writhing Absent Absent Absent Absent Absent Absent
13 Pupils Normal Normal Normal Normal Normal Normal
14 Urination Normal Present Normal Present Normal Present
15 Salivation Normal Normal Normal Normal Normal Normal
16 Skin colour Normal Normal Normal Normal Normal Normal
17 Lacrimation Normal Normal Normal Normal Normal Normal
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2). FRAP Assay:
Table- 16
Sample FRAP(FeSO4 Equivalents)
Ethanolic extract of Wattakaka volubilis
Linn
46.10±7.32
Data was expressed in fresh weight basis and is presented as mean ±SD. Data
subjected to statistical analysis (correlation between antioxidant activity and
phenolic content) using GraphPad Prism 5 statistical package. P< 0.0002.
3). ABTS:
ABTS radical scavenging activity of  ethanolic extracts of Wattakaka volubilis
Table- 17
SAMPLE 20(µg/ml)
40
(µg/ml)
60
(µg/ml)
80
(µg/ml)
100
(µg/ml)
Ethanolic
extract
0.5685 0.4727 0.3130 0.1957 0.1240
ABTS SCAVENGING
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4). TRAP:
Absorbance of the ethanolic extract of Wattakaka volubilis
Table- 18
SAMPLE
Absorbance
20(µg/ml) 40(µg/ml)
60
(µg/ml)
80
(µg/ml) 100 (µg/ml)
Ethanolic
extract 0.2372 0.2598 0.2635 0.2722 0.2786
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5). SUPER OXIDE SCAVENGING (SOS)
Absorbance of the ethanolic extract of Wattakaka volubilis
Table- 19
SAMPLE
% of SOS Activity
20(µg/ml) 40(µg/ml)
60
(µg/ml)
80
(µg/ml) 100 (µg/ml)
Ethanolic
extract 32.63 46.54 51.68 55.08 56.59
Figure- 4
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6). NITRIC OXIDE SCAVENGING (NOS)
Absorbance of the ethanolic extract of Wattakaka volubilis
Table- 20
SAMPLE
% of NOS Activity
20(µg/ml) 40(µg/ml)
60
(µg/ml)
80
(µg/ml) 100 (µg/ml)
Ethanolic
extract 25.73 29.13 36.62 48.28 55.09
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6.5. DAL INDUCED ACITIC TUMOR
1). Body weight analysis
Effect of Ethanolic extract of Wattakaka volubilis Linn on body weight of
mice challenged with Daltons lymphoma ascetic cells.
Table- 21
Experimental
groups
Body weight (gm) Decrease in
body weight
from 7th day
to 14th day
(gm)
%
Decrease
in body
weight
0 day 7th day 14th day
ONLY DAL 24
±1.211
31.5
±1.455**
37.17
±1.922***
--nil-- --nil--
DAL+5- FU
(20mg/kg)
23.17
±1.641
19.67
±0.9545 ns
18.00
±1.238 *
5.17 22.31
DAL + Extract
(100mg/kg)
24.83
±1.249
23.17
±1.376 ns
20.17
±1.046 *
4.66 18.76
DAL + Extract
(200mg/kg)
28.83
±2.023
26.17
±1.493 ns
22.50
±1.204*
6.33 21.17
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the experiment;
Statistical significance (p) calculated by one way ANOVA followed by dunnett’s,
P<0.05 calculated by comparing treated group with only 0 day of each group.
ns- Non significant
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BODY WEIGHT ANALYSIS
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[B]
[C]
[D]
Figure- 7 [A] - Shows the mice with only DAL, [B] - Shows the mice with
DAL+STD drug (5-FU 20mg/kg), [C] – Shows the mice with DAL+EXTRACT
(100mg/kg), [D] – Shows the mice with DAL+EXTRACT (200mg/kg).
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2). MEAN SURVIVAL (MST):
Effect of Ethanolic extract of Wattakaka volubilis Linn on survival time of
mice challenged with Daltons lymphoma ascetic cells.
Mean survival time and percentage increase in life span of various groups
Table- 22
Experimental groups Mean survival time indays %ILS
ONLY DAL 19.83±1.470 --nil--
DAL + 5-FU, 20mg/kg 40.83±1.424*** 105.90
DAL+ Extract
(100mg/kg) 27.17±1.778
* 37.01
DAL+ Extract
(200mg/kg)
34.00±2.309 ***
71.45
Values are expressed as the mean ± S.E.M.; Statistical significance (p)
calculated by one way ANOVA followed by dunnett’s, P < 0.0001,
ns – non significant calculated by comparing treated group with only DAL.
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3). EFFECT OF Wattakaka volubilis ON TUMOR VOLUME
Table- 23
Values are expressed as the mean ± S.E.M.; Statistical significance (p)
calculated by one way ANOVA followed by dunnett’s, p<0.0011,
ns– non significant calculated by comparing treated group with DAL group.
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Experiment
groups
ONLY
DAL
DAL + 5-FU,
(20mg/kg)
DAL + Extract
(100mg/kg)
DAL + Extract
(200mg/kg)
Tumor
volume
(ml)
10.00
±1.732
1.033
±0.08819***
7.1
±0.9504ns
3.9
±0.2082**
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4). EFFECT OF Wattakaka volubilis NON-VIABLE CELL COUNT
NON-VIABLE CELL COUNT
Table- 24
Experiment
groups
ONLY
DAL
DAL+5-
FU,
(20mg/kg)
DAL + Extract
(100mg/kg)
DAL + Extract
(200mg/kg)
Non-viable
cell count
1×106 564.3±81.53 173.7±33.89** 222.7±13.62**
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment; Statistical significance (p) calculated by one way ANOVA followed by
dunnett’s
P < 0.0034,
ns – non significant calculated by comparing treated group with DAL control
group.
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[C]
[D]
Figure-11 Effect of extract on Non-Viable Cell Count after 14 days treatment
[A]:  only DAL; [B]: DAL + 5-FU, 20 mg/kg body weight; [C]: DAL + EXTRACT 100
mg/kg body weight; [D]: DAL + EXTRACT 200 mg/kg body weight.
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6.7.1. EFFECT OF ETHANOLIC EXTRACT OF Wattakaka volubilis ON
HEMATOLOGICAL PARAMETERS:
1). RED BLOOD CELLS (RBC):
RBC count of experimental groups
Table- 25
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated groups and
ns-non significant.
RBC cell count
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Experiment
groups
NORMA
L
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg
)
DAL+
Extract
(200mg/kg)
RBC
(million/mm3
)
5.217
±0.07491
1.090
±0.03742**
*
4.872
±0.08360ns
4.595
±0.5749ns
5.767
±0.47
38ns
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2). HAEMOGLOBIN
HAEMOGLOBIN values of the experimental animals
Table- 26
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment; P<0.0001, between tumor control and treated groups.
ns-non significant.
Hb
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Experimen
t
Groups
NORMA
L
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg
)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg
)
Hb (%) 15.50
±0.2033
5.817
±2.038***
12.57
±0.6931ns
10.88
±0.8167*
15.15
±0.2680ns
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3). HEMATOCRIT
HEMATOCRIT of the experimental animals
Table- 27
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment, P<0.0001, between tumor control and treated group.
ns-non significant.
HEMATOCRIT
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Experimen
t groups
NORMA
L
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
Hematocrit
(%)
43.72
±0.7631
10.92
±1.339***
34.98
±0.3609**
28.88
±0.5839***
36.77
±3.443*
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4). MCV
The MCV values of the experimental animals
Table- 28
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0015, between tumor control and treated group.
ns-non significant.
MCV
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Experiment
groups
NORMA
L
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg
)
MCV
(fl)
43.30
±0.2352
31.20
±3.808**
42.33
±1.022ns
34.24
±2.527*
39.05
±0.6158ns
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5). MCH
The MCH values of the experimental animals
Table- 29
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated groups.
ns-non significant.
MCH
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Experiment
groups NORMAL
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
MCH
(pg)
29.47
±0.4145
15.63
±0.4944
***
24.17
±1.390 **
20.35
±0.3528 ***
29.98
±1.966 ns
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6). MCHC
The MCHC values of the experimental animals
Table- 30
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated group.
ns-non significant.
MCHC
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Experiment
groups NORMAL
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
MCHC
(%)
31.50
±0.3907
15.45
±0.3452
***
31.83
±0.4096 ns
21.35
±0.3547 ***
28.85
±0.4958 ***
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7). WBC
WBC count of experimental groups
Table- 31
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0002, between tumor control and treated group,
ns- non significant.
WBC
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Experiment
groups NORMAL
ONLY
DAL
DAL+ 5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
Total WBC
(1×103/mm3)
8890
±535.4
27425
±4289 ***
11967
±757ns
15360
±2025ns
16383
±2541ns
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6.7.2. SERUM BIOCHEMICAL PARAMETERS:
1). SERUM GLUTAMATE OXALOACETATE TRANSAMINASE (SGOT)
Serum SGOT Levels.
Table- 32
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment; P<0.0001, between tumor control and treated groups.
ns-non significant.
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
SGOT(u/l) 146±7.743 80.67
±3.461 ***
110.2
±0.7032 ***
65.50
±3.374 ***
85.33
±4.006 ***
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2). Alkaline Phosphates (ALP)
Serum ALP levels
Table- 33
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0011, between tumor control and treated group.
ns-non significant
Alkaline Phosphatase (ALP)
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
20mg/kg
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
ALP(u/l) 73.67
±1.116
146.3
±9.783 ***
83.67
±15.18 ns
112.7
±12.49 ns
93.5
±12.89 ns
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3). UREA
Serum UREA values
Table- 34
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated group.
ns-non significant.
UREA
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
UREA 49
±3.134
26.30
±1.232***
44.57
±2.673ns
33.32
±2.920 ***
41.10
±1.794 ns
Chapter-6 Results and Discussion
Dept. of Pharmacology 97 JKK Nattraja College of Pharmacy
4). URIC ACID
Serum URIC ACID values
Table- 35
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0136, between tumor control and treated groups.
ns-non significant.
URIC ACID
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
URIC
ACID
5.550
±0.1384
3.267
±0.5463 *
5.867
±0.6781 ns
5.150
±0.7702 ns
6.167
±0.5584 ns
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5). BILURUBIN
Serum BILURUBIN values
Table- 36
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0081, between tumor control and treated group.
ns-non significant.
BILURUBIN
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Figure- 23
Experiment
group NORMAL
ONLY
DAL
DAL+5-
FU,
(20mg/kg)
DAL +
Extract
(100mg/kg
)
DAL +
Extract
(200mg/kg)
BILURUBIN 0.4500
±0.06708
0.1000
±0.02582**
0.4167
±0.06009 ns
0.2167
±0.08724 ns
0.3000
±0.08563 ns
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6). TRIGLYCERIDES (TGL):
Serum TGL levels
Table- 37
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment, P<0.0007, between tumor control and treated group.
ns-non significant.
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL +
Extract
(100mg/kg)
DAL
+Extract
(200mg/kg)
TGL(mg/dl) 153.4
±22.93
177.6
±15.67ns
48.05
±4.622 **
144.4
±31.30 ns
100.6
±11.18ns
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7). CREATININE (CR)
Serum CR levels
Table- 38
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0038, between tumor control and treated group.
ns-non significant.
CREATININE(CR)
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Figure- 25
Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL+
Extract
(100mg/kg
)
DAL+
Extract
(200mg/kg)
CR(mg/dl) 0.3667
±0.03333
0.4167
±0.06009 ns
0.2167
±0.04014 ns
0.3167
±0.03073 ns
0.2000
±0.03651 *
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8). TOTAL CHOLESTROL
Serum CHOLESTROL values
Table- 39
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0027, between tumor control and treated group.
ns-non significant.
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Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL
+Extract
(100mg/kg)
DAL
+Extract
(200mg/kg)
TOTAL
CHOLESTROL
43.40
±3.144
47.57
±5.0 ns
25.57
±0.5714*
47.62
±6.060 ns
41.25
±2.043 ns
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6.7.3. IN-VIVO ANTI OXIDANT STUDIES:
A. ENZYMATIC ANTI-OXIDANT ACTIVITY
1). Total Protein (TP):
Table- 40 Serum TP level
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0021, between tumor control and treated group.
ns-non significant.
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Figure- 27
Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL +
Extract
(100mg/kg)
DAL +
Extract
(200mg/kg)
TP(g/dl) 0.5260
±0.00954
0.5190
±0.0316 ns
0.5990
±0.00517*
0.5800
±0.00546 ns
0.5960
±0.0122 *
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2). ESTIMATION OF SUPEROXIDE DISMUTASE (SOD) ACTIVITY:
SOD levels of liver
Table- 41
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated group.
ns-non significant.
SOD
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Figure- 28
Experiment
group NORMAL ONLYDAL
DAL+
5-FU,
20mg/kg
DAL
+Extract
(100mg/kg)
DAL
+Extract
(200mg/kg)
Liver 0.2060
±0.00530
0.1520
±0.00478***
0.1940
±0.00387ns
0.1690
±0.00699***
0.1890
±0.00490ns
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3). CATALASE
Catalase levels of levels of liver
Table- 42
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment, P<0.0009, between tumor control and treated groups and ns-non
significant.
CATALASE
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Figure- 29
Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
20mg/kg
DAL
+Extract
(100mg/kg)
DAL
+Extract
(200mg/kg)
Liver 0.8280
±0.00909
0.7310
±0.0195**
0.8400
±0.0111 ns
0.7780
±0.0201 ns
0.8380
±0.0265ns
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4). ESTIMATION OF GLUTATHIONE PEROXIDASE (GPx) ACTIVITY:
GPx levels of liver
Table- 43
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0194, between tumor control and treated group.
ns-non significant.
GPx
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Figure- 30
Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL
+Extract
(100mg/kg)
DAL
+Extract
(200mg/kg)
Liver 0.320
±0.00480
0.250
±0.0219*
0.299
±0.00967 ns
0.262
±0.0176 *
0.277
±0.0142 ns
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B. NON-ENZYMATIC ANTIOXIDANT ACTIVITY
1). Estimation of reduced glutathione (GSH) activity:
GSH levels of liver
Table- 44
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0026, between tumor control and treated group.
ns-non significant.
GSH
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Figure- 31
Experiment
group NORMAL
ONLY
DAL
DAL+5-FU,
(20mg/kg)
DAL
+Extract
(100mg/kg
)
DAL +
Extract
(200mg/kg
)
Liver 0.422
±0.00408
0.273
±0.0264
***
0.393
±0.0363 ns
0.328
±0.0119 *
0.344
±0.0298 ns
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2). ESTIMATION OF LIPID PEROXIDATION (LPO) ACTIVITY:
LPO levels in liver
Table- 45
Values are expressed as the mean ± S.E.M., (n = 6) on day 14 of the
experiment P<0.0001, between tumor control and treated group.
ns-non significant.
LPO
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Figure- 32
Experiment
group NORMAL ONLYDAL
DAL+5-
FU,
(20mg/kg)
DAL
+Extract
(100mg/kg)
DAL+
Extract
(200mg/kg)
Liver 0.8020
±0.02839
0.8469
±0.05823
ns
0.5270
±0.04364 ***
0.6526
±0.03949 ns
0.5719
±0.03959 **
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6.8. HISTOLOGY OF LIVER STAINED HAEMOTOXYLIN-EOSIN (×100)
OF MICE FROM THE DIFFERENT GROUPS
[ A ]
[ B ]
[ C ]
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[ D ]
[ E ]
Figure- 33, [A]- shows normal liver, [B]- shows only DAL, [C]- shows DAL+
Standard (5-FU, 20mg/kg), [D]- shows DAL+ Extract (100mg/kg), [E]- shows
DAL+ Extract (200mg/kg)
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DISCUSSION
The preliminary phytochemical studies of ethanolic extract of Wattakaka
volubilis (L.) indicated the presence of flavonoids, glycosides, phenols and
triterpenoids. The observed antitumour, and antioxidant activities may be due to the
presence of any of these compounds in Wattakaka volubilis.
Bioactive antioxidant levels:
Flavonoids are a group of effective antioxidants which are present
abundantly throughout the plant kingdom. Flavonoid and related compound are
effective in scavenging DPPH radical, hydroxyl radical etc and also have metal-
chelating capacity Flavonoids are found to exhibit numerous biological activities
like vasodilaton, anticarcinogenic, anti-inflammatory, antibacterial, immune-
stimulating, antiallergic, and antiviral effects.
Phytosterols (PS) or plant sterols were structurally similar to cholesterol. The
most common PS are β-sitosterol, campesterol and stigmasterol. The PS acts on
membrane structure and function of tumor and host tissue, and also on signal
transduction pathways. They regulate tumor growth and apoptosis, immune function
of the host and cholesterol metabolism of the host.
Free radicals may be defined as any species that are capable of independent
existence and possessing one or more unpaired electrons. These radicals can react
with other molecules in different ways. The net effect is that radical donates its
unpaired electron to another molecule and the other molecule then becomes a
radical.
In-vitro antioxidants:
The DPPH assay method is based on the reduction of DPPH, a stable free
radical. The free radical DPPH with an odd electron gives a maximum absorption at
517 nm (purple colour). As the odd electron of the radical becomes paired off in the
presence of a hydrogen donor. e.g., a free radical scavenging antioxidant, the
absorption strength is decreased and results in decolorization (yellow colour) with
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respect to the number of electrons captured (Blois, 1958). More the decolorization
more is the reducing ability. This test has been the most accepted model for
evaluating the free radical scavenging activity of any new drug. The percent DPPH
scavenging activities of Wattakaka volubilis extract was summarized in (Table – 17)
The decolorization of ABTS cation radical is an unambiguous way to
measure the antioxidant activity of phenolic compounds. Thus the ability of a
compound to scavenge ABTS radical can demonstrate oxygen radical absorbance
capacity. Ethanol extracts of Wattakaka volubilis showed a potent ABTS radical
scavenging activity. (Table 19). The absorbance was found to be increased with the
increase in concentration.
FRAP assay  measures  the  reducing  ability  of antioxidants  against
oxidative  effects  of  reactive oxygen species. Electron donating anti-oxidants can
be described as reductant or reducing agent and inactivation of oxidants by reductant
can be described as redox reactions. In the current study ethanolic extracts of
Wattakaka volubilis exhibited a significant scavenging activity in ferrous sulphate
equivalents.
TRAP is the total radical trapping antioxidant parameter. The ethanolic
extract of Wattakaka volubilis showed free radical scavenging activity which was
found out by the absorbance of the sample at different concentrations. ( Table 20).
The max absorbace was observed in 100 µg/ml of extract.
NOS and SOS activity of ethanolic extract of Wattakaka volubilis were
checked which showed a potent activity. The super oxide scavenging was found to
increase with concentration of extract (Table 21) and max absorbance was found at
100 µg/ml of extract. The nitric oxide scavenging activity was also observed and the
maximum absorbance was observed at 100 µg/ml of extract.
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DAL-induced ascitic anticancer studies
The reliable criteria for judging the value of an anticancer drug is the
prolongation of the life span of animals. In DAL tumor bearing mice, a regular rapid
increase in ascitic tumor volume was observed. The DAL bearing mice co-
administered with ethanolic extract of Wattakaka volubilis at 100 and 200 mg/kg
body weight showed significant increment in the average life span of animals
compared to that of the tumor control group. However, the percentage increase in
body weight, tumor cell volume, and number of viable tumor cells were found to be
significantly lesser than the tumor control animals, indicating the anticancer effect of
the extract. (Badami et al., 2003) These results could indicate either a direct
cytotoxic effect of Wattakaka volubilis on tumor cells or an indirect local effect,
which may involve macrophage activation and vascular permeability inhibition.
Hence, the observed anticancer activity of Wattakaka volubilis leaves may be due to
the cytotoxic properties.
The mean survival time of extract 100mg/kg and 200mg/kg were found to be
significant to that of standard drug. The mean survival time of 200mg/kg was found
to be  more significant to that of standard drug. The % decrease in body weight was
also observed for 14 days and was found to be significant in extract treated group
with respect to standard drug; wherein 100mg/kg showed moderately significant and
200mg/kg showed highly significant to that of standard drug treated group..
The tumour volume was measured after 14days of treatment. In both of
extract treated group, the tumour volume was lesser than that of the DAL control
group. The tumour volume of 200mg/kg extract treated group was more significant
to that of standard as compare to 100mg/kg extract treated group. The non viable
cell count was also observed from the peritoneal volume and compared with that of
standard. The 200mg/kg group showed moderate effect compared to that of standard
and on the other hand the 100mg/kg extract treated group was less significant
compared to standard.
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Haematological parameters
In cancer chemotherapy the major problems are of myelosuppression and
anaemia (Price, Greenfield, 1958), (Hogland HC, 1982,)
Anaemia  encountered  in  tumour  bearing mice  is mainly  due  to
reduction  in RBC and Hb% and  this may occur either due to  iron deficiency or due
to hemolytic or myelopathic conditions. However, the elevation of WBC levels may
be due to its adverse effect on the haemopoietic system. ( Fenninger, Mider, 1954)
The MCH, MCV, MCHC and Hematocrit values also gets affected based
on the RBC count and Hb values.
In cancer condition the RBC, Hb and all other blood related parameters
(MCH, MCV, MCHC and Hematocrit) gets decreased leading to anaemia and the
WBC, platelet factors and other WBC related parameters gets increased which
shows that the immune system of the animal is affected, and also shows the presence
of infections in the body.
The RBC and all blood related parameters got decreased in all tumour
control groups signifying the presence of tumour cells. The WBC and related levels
were found increased in all the groups. The extract group 200mg/kg showed
significant reversal in the parameters signifying the activity of extract and
significant values compared with that of control. The values were almost equal to
that of control group. The standard drug and extract 100mg/kg also showed
significant activity in reversal of the parameter but moderately less significant than
200mg/kg group.
Biochemical parameters
The inoculation of DAL cells caused significant increases in the levels of
TGL, TP, TC, ALP, and there is no significant change in the levels of ASAT and
ALAT in the serum of tumor control group as compared to the normal group. The
urea, uric acid and bilurubin levels found to be decreased in group than the normal
levels.
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The treatment with ethanolic extract of Wattakaka volubilis at 100 and 200
mg/kg body weight reversed these changes towards the normal levels. Most of the
values were found to be significant. The results with standard drug treated group
gave almost similar to that of the extract treated groups. (Moss, Butterworth,
1974).
Serum SGOT, ALP levels were found to be less for treated group 200mg/kg
than that of the control and only DAL groups and also the standard drug. The urea,
uric acid and TG levels of standard drug was found to be less than that of control
and only DAL groups. The 100mg/kg showed moderately significant activity
compared to that of standard drug group.
The bilurubin and TC values of the only DAL groups was very much less
than that of the control group. The extract 200mg/kg group showed significant
activity and the values almost similar to that of the normal groups.
The creatinine levels of the only DAL groups got increased and the extract
100mg/kg group showed significant values that nearly coinciding with that of the
normal groups.
In-vivo Antioxidant studies
The antioxidant nature of Wattakaka volubilis was also evaluated by the in-
vitro antioxidant studies. Plants with high total phenol content are known to possess
strong antioxidant properties. The observed antioxidant activity may be due to the
high phenolic, or flavanoid or may be due to phytosterol content of the extract.
It was observed that tumor cells produced more peroxides; when they
proliferate actively after inoculation of tumor. This rise in peroxides indicated the
occurrence of intensification of oxygen free radical production. Cells which are
equipped with enzymatic antioxidant mechanisms play an important role in the
elimination of free radicals.(Lee, et al., 2004)
Lipid peroxidation mediated by free radicals considered being a primary
mechanism of cell membrane destruction and cell damage. The oxidation of
unsaturated fatty acids in biological membrane leads to reduction in membrane
fluidity and disruption of membrane structure and function. MDA, the end product
of lipid peroxidation was also reported to be higher in carcinogenous tissue than the
non-pathological tissues. Increase in levels of TBARS indicate enhanced lipid
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peroxidation leading to tissue injury and failure of antioxidant defense mechanism to
prevent the formation of excess free radicals.
Both the extract treated groups 100mg/kg & 200mg/kg shows a significantly
decrease in the liver TBARS and the values were significant to that of the normal
animals. The lipid peroxidation values of standard drug were much more less than
that of normal group.
The active role of GSH against cellular lipid peroxidation has been well
recognized and thereby reduces the glutathione (GSH) activity. GSH can act either
to detoxify the reactive oxygen species such as H2O2 or reduce lipid peroxidation.
The increased the levels of glutathione content indicates antioxidant activity.
The GSH values of the standard drug treated group and extract 100mg/kg
treated group were almost equal and are nearly significant with that of the normal
group. The GSH values of the extract treated group 200mg/kg were highly
significant with that of the control groups. (Navarro et al., 1997)
SOD is a chain breaking antioxidant and is found in all aerobic organisms. It
is a  metaloprotein widely distributed in all cells and plays an important protective
role against ROS-induced Oxidative damage. The free radical scavenging system
catalase, which are present in all major organisms in body of animals and human
beings and is especially concentrated in liver and erythrocytes . Both enzymes play
an important role in the elimination of ROS derived from the redox process of
xenobiotic in liver tissues. It was suggested that catalase and SOD are easily
inactivated by lipid peroxidase or ROS. In correlation it has been reported that DAL
bearing mice shows decreased levels of SOD activity and this may be due to loss of
MN++ SOD activity in liver and inhibition of catalase activity in tumor cell lines also
reported.
In this study, catalase and SOD were significantly elevated by administration
of extract 200mg/ kg which was almost significant with that of the control group.
(Kavitha, Manoharan, 2006), (Valenzuela, 1990)
The TP level of only DAL group should be increased indicating the damage
of the liver cells. The extract group 200mg/kg values were significant with that of
the normal group.
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Histopathological analysis
Histopathological observation of liver under a light microscope was done to
observe the effect of ethanolic extract of Wattakaka volubilis on the anatomical
integrity of the cells.
The liver of normal animal showed normal histological appearance and mild
sinusoidal vein dilation, congestion with mild periportal and lobular inflammation.
The only DAL group showed congestion and dilatation of central vein and
sinusoids, few portal tracts showing peroportal inflammation and foci show lobular
necrosis with neutophils.
The animals treated with standard 5-FU at 20 mg/kg I.P shows hepatic tissue
with mild sinusoidal and central vein dilatation and congestion with mild periportal
and lobular inflammation.
The animals treated with ethanolic extract of Wattakaka volubilis at
100mg/kg and 200mg/kg body weight showed almost similar histological
appearance of liver cells, except for a few lymphocytes and neutrophils in a
particular laminated structure and were found to be quiet better than that of only
DAL bearing group.
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7. CONCLUSION
The present pre-clinical investigation was carried out to evaluate the
anticancer activity of ethanolic extract of Wattakaka volubilis leaves in DAL
induced lymphoma in mice with it’s antioxidant effect.
It was found that there was significant increase in the life span with
decreased tumour volume in all the extract treated mice. The haematological and
antioxidant status got improved in DAL with extract treated groups.. The effect was
also found to be dose dependent. The biochemical and histopathological studies
supported the anticancer and antioxidant properties of the extract.
The antioxidant nature of Wattakaka volubilis leaf extract was confirmed by
in-vitro antioxidant studies which showed significant results at various
concentrarions.
The results of present investigation proved that ethanolic extract of
Wattakaka volubilis leaf was found to be effective in inhibiting cancer growth by in-
vivo screening and also provide some insights in to the possible mechanism by
which Wattakaka volubilis leaf extract brings about inhibition in growth of DAL
cells in mice. Thus these observations indicate that the plant leaf was having
antioxidant property and also a protective effect against Dalton’s ascites lymphoma.
The present studies also suggest the herb is cost effective and alternative in
treatment of tumour and related disorders.
Further studies were essential to elucidate and evaluate both it’s molecular
mechanism of action and potential usefulness of Wattakaka volubilis as a alternative
drug in cancer therapy.
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